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INTRODUCTION
Plasminogen activators (PA) are serine proteases that convert the
zymogen plasminogen to the active protease plasmin by the cleavage of an
Arg-Val peptide bond.Two types of PA have been identified by
functional differences, molecular weight (MW), and immunologic
activities: urokinase-type (uPA) and tissue-type (tPA) with MW of 30-55
and 70 kD, respectively (Dano et al., 1985).The PA are products of two
distinct genes which have been isolated and sequenced (Degen et al.,
1987; Rajput et al., 1987).Tissue-type PA displays a high affinity for
fibrin, thus it is considered as the key enzyme in thrombolysis (Astrup,
1978).Urokinase-type PA has been suggested to participate in the
localized proteolysis of the extracellular matrix accompanying tissue
remodeling and cellular migration (Blasi et al., 1987).
Beside many types of normal and malignant cells, PA is produced by
cultured embryos of mice (Strickland et al., 1976), rats (Liedholm and
Astedt, 1975), swine (Mullins et al., 1980), cattle (Menino and
Williams, 1987), and sheep (Menino et al., 1989).Although the function
of PA in early embryo development is obscure, it was implicated in
cellular migration and implantation in mouse embryos (Sherman et al.,
1976; Strickland et al., 1976), tissue remodeling and proliferation in
swine embryos (Fazleabas et al., 1983), and facilitating embryo hatching
in cattle and sheep (Menino and Williams, 1987; Menino et al., 1989).2
The extracellular proteolytic activity of the PA/plasminogen
system is regulated by a delicate balance between PA, plasminogen, and
their endogenous inhibitors.Several agents have been shown to modulate
plasminogen activation in a variety of cell types.Gonadotropins
stimulated PA activity in rat granulosa cells (Strickland and Beers,
1976; Reich et al., 1985; Canipari and Strickland, 1986), cultured human
cytotrophoblasts (Queenan et al., 1987), and rat and bovine Sertoli
cells (Lacroix et al., 1981; Hettle et al., 1986; Jenkins et al., 1988).
The effects of gonadotropins were presumably mediated by cyclic
adenosine monophosphate (cAMP).Estrogen stimulated production of PA in
human breast carcinoma cell lines (Dickerman et al., 1989) and enhanced
plasminogen uptake by the mouse uterus (Finlay et al., 1983).
Glucocorticoids, such as dexamethasone, inhibited PA activity in rat
granulosa cells (Harlow et al., 1987) and bovine Sertoli cells (Coombs
and Jenkins, 1988) by stimulating the production of PA-inhibitors (PAI).
Similarly, progesterone was found to stimulate production of protease
inhibitors in mouse and pig uteri (Harpel et al., 1966; Mullins et al.,
1980), thus inhibiting fibrinolytic activity within the uterus during
specific stages of the estrous cycle.Phorbol myristate acetate (PMA)
and retinoic acid (RA) are also potent inducers of PA production in a
number of different cells and tissues (Strickland and Mandavi, 1978;
Wilson and Reich, 1978; Opdenakker et al., 1983; Santel and Levin,
1988).
Hormonal regulation of embryonic PA production has not been
studied.Therefore, the objective of this study was to evaluate the
effects of progesterone (P), estradiol -17fl (E2), dexamethasone (Dex),
retinoic acid (RA), dibutyryl cyclic AMP (dbcAMP), and phorbol myristate3
acetate (PMA) on PA production in cultured bovine embryos.Changes in
embryonic size were also evaluated to assess embryo viability in
response to the hormonal treatments.4
LITERATURE REVIEW
The significance of proteolytic enzymes in biological control
mechanisms has been recognized since the turn of the century when
Bayliss and Starling (1902) described the role of secretin in
stimulating the production of pancreatic juice.Several proteases have
been discovered in the gastrointestinal tract of higher animals which
facilitate digestion and absorption of nutrients.Another class of
proteolytic enzymes resembling the gastrointestinal proteases was found
in blood plasma, sperm, and many other tissues.These enzymes
participate in various control functions such as coagulation,
fibrinolysis, tissue remodeling and cellular migration.
Plasminogen activators (PA) are serine proteases that cleave the
inactive zymogen, plasminogen, to the active enzyme plasmin.
Plasminogen activators and plasmin are the major components of the
fibrinolytic system and the main physiological role for this system is
the dissolution of fibrin clots formed in blood vessels.Several other
functions of PA have been proposed in a variety of normal and abnormal
processes such as tissue remodeling, ovulation, tumor proliferation, and
cellular migration.
This literature review will be divided into three parts.The
first part will be devoted to the biochemical properties of plasminogen,
PA, and their inhibitors.The second part will cover the various
functions of these enzymes including their physiologic role in the
reproductive system.The final part will discuss the regulatory
mechanisms controlling PA activity.5
I.Biochemical Properties of Plasminogen and Plasminogen Activators
1. Plasminogen and Plasmin
Plasminogen is the inactive precursor of the proteolytic
enzyme plasmin.Highly purified plasminogen can be obtained from
several species by a combination of affinity binding to agarose L-
lysine columns and ion-exchange chromotography on carboxymethyl-
cellulose or diethylaminoethyl-Sephadex.Human plasminogen
isolated by such methods has a molecular weight (MW) of 83-92 kD.
It is composed of a single chain glycoprotein consisting of 790
amino acids, with a glutamine residue at the amino-terminus and an
asparagine residue at the carboxy-terminus.Two major forms of
plasminogen have been identified:one containing glutamine at the
amino-terminus (Glu-plasminogen), and the other having lysine at
the amino-terminus (Lys-plasminogen) (for a review, see Christman
et al., 1977).Glu-plasminogen has an electrophoretic mobility
similar to plasminogen from fresh plasma, whereas Lys-plasminogen
has a higher isolectric point, suggesting that Lys-plasminogen has
been proteolytically modified during the purification procedure
(Wallen and Wiman, 1970).When purified Glu-plasminogen is treated
with plasmin, a small peptide of about 8 kD is cleaved from the
amino-terminal to yield a modified plasminogen (Lys-plasminogen)
with Lys-77 as the new amino-terminus (Ryan, 1987).
Plasmin is generated from either Glu-plasminogen or Lys-
plasminogen by proteolytic cleavage of a single peptide bond
between Arg-560 and Val-561.Plasmin is a two chain molecule in
which the polypeptide chains are held together by two disulfide
bonds.The heavy (A) chain has a molecular weight of 48-63 kD and6
contains the carbohydrate units as well as the lysine binding
sites.The light (8) chain of plasmin has a molecular weight of
20-25 kD and contains the serine protease portion of the molecule.
The light chain has amino acid sequence homologies with other
serine proteases, such as trypsin and chymotrypsin, and has an
active site composed of Ser, His and Asp.Plasmin has typical
trypsin-like specificity and hydrolyzes proteins at Lysyl and
arginyl bonds.Plasmin cleaves many substrates such as casein,
protamine, cell membrane proteins and some hormones.It displays a
high specificity toward fibrin and fibrinogen and it has been shown
that plasmin is 50-100 times faster than trypsin in clot lysis.
The difference in the rate of hydrolysis is due mainly to the
presence of lysine-binding sites, which are not present in trypsin.
(For reviews, see Dano et al., 1985; Christman et al., 1977; Ryan,
1987).
There is a high degree of homology in plasminogen and plasmin
among the different mammalian species.Summaria and coworkers
(1973) compared highly purified preparations of cat, dog, rabbit,
and bovine plasminogens with human plasminogen, and found that the
molecular weights among plasminogens were similar.Moreover, they
found that the heavy and light chains of plasmin from these
different species were similar to the human.The complete amino
acid sequence of human, bovine, and porcine plasminogen have been
established and demonstrate an overall homology of 78%.Highly
conserved sequences were found among the light chains (80%
homology) and heavy chains (83%).Despite the similarities in
sequence and molecular features, plasminogens of various species7
differ in their activation with streptokinase.Human plasminogen
is efficiently activated by trace amounts of streptokinase, whereas
bovine, ovine, and porcine plasminogens are not activated by such
meager amounts.This is probably due to differences in the amino
acid sequence in certain regions of the plasminogen from these
species (Schaller and Rickli, 1988; Schaller et al., 1985).
The heavy (A) chain of plasmin is characterized by five triple
loop structures known as kringles.Kringle domains are also
present in prothrombin, urokinase, and several other fibrinolytic
proteins.The kringle structure has a molecular weight of about 10
kD, and it is crosslinked internally by three cystine linkages.
These domains play a very important role in specific protein-
protein interactions.Several workers suggested that kringles
mediate the attachment of plasminogen or plasmin to the fibrin
matrix of blood clots.Moreover, these kringles are able to bind
lysine, and thus facilitate fibrin-binding capability of
plasminogen (Petros et al., 1988; Thewes et al., 1988).
Receptors for plasminogen and plasmin have been identified in
human tumor cell line SW 1116.These receptors are the same for
both proteins, but exhibit higher affinity for plasmin.Bound
plasmin retains its enzymatic activity, and may activate pro-
urokinase resulting in the formation of urokinase, which in turn
increases the binding of plasminogen and plasmin.Ultimately, this
process increases the concentration of plasmin at the surface of
tumor cells, enabling them to degrade the connective tissues and
component proteins of the basement membrane (Burtin and Fondaneche,
1988).8
Plasma contains several protease inhibitors which regulate the
fibrinolytic system.a2-antiplasmin (AP) and a2-macroglobulin are
the most important inhibitors of plasmin.a2-antiplasmin is
characterized by rapid inactivation of plasmin, while a2-
macroglobulin exerts its action only when AP levels are depleted
(Dann et al., 1985).The fast-reacting property of AP is
attributed to the ability of AP to bind Lys-binding sites of
plasmin.This association brings together the active site of
plasmin with the reactive site of AP, resulting in a covalent
complex which is enzymically inactive.A recent study showed that
the C-terminal lysine residue of AP plays a major role in binding
AP to plasmin.a2-antiplasmin will lose its ability to inhibit
plasmin when the C-terminal of AP is cleaved by carboxypeptidase-B
(Hortin et al., 1988).a2-antiplasmin is homologous with
antithrombin III, a2-antitrypsin, and other serine-proteinase
inhibitors (serpins).It is a single-chain glycoprotein with a MW
of 70 kD, and consists of 452 amino acids (for review see Rijken et
al., 1988).
2.Plasminogen activators
Christensen (1945) was the first to demonstrate that
plasminogen can be converted into plasmin by a streptococcal factor
(for review, see Christman et al., 1977).Two major plasminogen
activators have been identified by functional differences and by
differences in molecular weight and immunological reactivities:
Urokinase-type plasminogen activator (uPA) and tissue-type
plasminogen activator (tPA) with molecular weights of 30-55 and 70
kD, respectively (Dann et al., 1985).9
a.Urokinase-type plasminogen activator.
Urokinase-type (uPA) plasminogen activator is the best
characterized of the endogenous PA.It is a serine protease
isolated from human urine, as the name suggests.Urokinase is
a glycoprotein synthesized as an one-chain proenzyme (MW=55
k0) with little or no PA activity.The zymogen is converted
to the active enzyme (MW=55 kD) by limited proteolysis with
plasmin (Vassalli et al., 1984).Active urokinase consists of
two polypeptide chains bridged by a disulfied bond, and exists
in high and low molecular weight forms (55 and 33 kD,
respectively).The high molecular weight form consists of a
catalytic subunit (B-chain) with a MW of about 33 kD which is
homologous to the catalytic subunit of other serine proteases.
The non-catalytic unit (A-chain) of the high MW form contains
one kringle domain and a domain required for interaction with
cellular receptors.The low MW form is a proteolytic product
of the two-chain uPA lacking most of the A chain but retaining
the active site-containing the B chain (Dano et al., 1985;
Hart and Rehemtulla, 1988; Vassalli et al., 1985).
Recent studies indicate the presence of a single-chain
form of uPA (scuPA), and it has been purified from several
natural sources, including urine (Lijnen et al., 1986).This
form, in contrast to one-chain pro-urokinase, has considerable
interinsic plasminogen-activating activity.When scuPA and
plasminogen are combined, two-chain uPA (tcuPA) and plasmin
were formed.Addition of plasmin inhibitors to this mixture
abolishes the generation of tcuPA but not the activation of10
plasminogen to plasmin, suggesting that scuPA activates
plasminogen directly (Lijnen et al., 1986).A model has been
proposed to explain the role of scuPA in plasminogen
activation.In the first reaction scuPA directly activates
plasminogen to plasmin, plasmin then converts scuPA to tcuPA,
and in the final reaction, plasminogen is converted to plasmin
by tcuPA (Lijnen and Collen, 1988).Lijnen and his colleague
(1988) also used site-directed mutagenesis of certain amino
acids comprising recombinant scuPA (rscuPA) to study the
enzymatic properties of the scuPA and tcuPA.Their findings
suggested that the enzymatic properties of rscuPA are
dependent on the amino acids in position 158 and 159.
Substitution of the basic amino acid in position 158 resulted
in a 10-20 fold reduction of the catalytic efficiency of
scuPA, but yielded a fully active tcuPA.The presence of Ile
in position 159 is the primary determinant for the activity of
the single and two-chain derivatives.They concluded that
scuPA constitutes the primary active principle; however, the
catalytic efficiency of tcuPA is higher than scuPA.Single
chain uPA can be converted by thrombin to an inactive two-
chain derivative (thrombin-derived tcuPA), which can be
converted to active two-chain uPA by treatment with plasmin.
The active tcuPA generated from thrombin-derived tcuPA is
similar to tcuPA obtained by digestion of intact scuPA with
plasmin (Lijnen et al., 1987).
The previous findings of Lijnen and his colleagues (1986)
have been challenged by several workers.Petersen and his11
coworkers (1988), believed that human and murine cells
released uPA as a single-chain proenzyme that has little or no
plasminogen-activation capacity.They compared the
plasminogen activating capacity of single and two-chain uPA
using125I-plasminogen conversion assay in the presence of
high amounts of plasmin inhibitor.Single-chain uPA has a
maximal intrinsic activity of about 0.4% of the two-chain uPA
activity.They noted that one-chain uPA has a variety of
other features similar to the one chain proenzyme forms of
other serine proteases.Therefore, they classified scuPA as a
genuine proenzyme form of uPA.
The complete amino acid sequence of human and porcine uPA
has been established.Moreover, the mRNA of uPA has been
identified and characterized, and cDNA have been constructed.
Using this information, the human uPA gene was identified to
be in the long arm of chromosome 10 (for review, see Dano et
al., 1985).Comparisons of the murine uPA gene to porcine and
human uPA genes revealed a high degree of evolutionary
sequence conservation of the base pair constituents of exons
and introns (Degen et al., 1987).
Urokinase type PA is synthesized and released by a wide
variety of cell types, such as monocytes, macrophages,
polymorphonuclear leukocytes, implanting trophoblasts, and
malignant tumor cells (Vassalli et al., 1984; Strickland et
al., 1976; Markus et al., 1980).Specific uPA receptors were
detected in human monocytes and cells of monocyte line U937.
These membrane receptors bind the high MW uPA (55 SO) with12
high affinity, but do not bind the low MW uPA (33 kD).These
findings demonstrate the importance of the non-catalytic A-
chain of 55 kD uPA, and suggest the presence of a cellular
interaction domain within the A-chain of uPA.Enzyme-bound
uPA has a great importance in initiating localized lysis of
extracellular matrix, thereby facilitating monocyte migration
(Vassalli et al., 1985).
Urokinase catalyzes the conversion of plasminogen to the
active protease, plasmin, by the hydrolysis of Arg-560-Val-561
peptide bond.Plasminogen is the only well-documented protein
substrate for uPA (Dano et al., 1985); however, Keski-Oja and
Vaheri (1982) found that purified urokinase cleaved a 66 kD
protein component of pericellular matrix of cultured human
lung fibroblasts.The resulting 62 kD protein remained
attached to the matrix, suggesting that it was derived from
the 66 kD protein.Therefore, they concluded that the 66 kD
protein was the first known extracellular target for
urokinase.Baron-Van Evercooren and coworkers (1987) showed
that the proliferation of Schwann cells from newborn rat
dorsal root ganglia is stimulated in a dose-dependent manner
by urokinase.This mitogenic effect was observed in the
absence of plasminogen, suggesting that plasminogen was not
the substrate of urokinase in the developing nervous system.
Plasminogen activation by uPA is species specific to some
degree.Chicken uPA fails to activate human plasminogen, but
human uPA activates chicken plasminogen (Dano et al., 1985).13
b.Tissue-type plasminogen activator.
Tissue-type PA has been identified and isolated from
several different tissue extracts:human uterus, porcine
kidney, heart and ovary, and many other normal, as well as
malignant, tissues (Dano et al., 1985).Tissue-type PA is a
serine protease synthesized as a proenzyme with a MW of 70 kD
and composed of 530 amino acids and 3-4 N-glycosylation sites.
Limited proteolysis by plasmin, kallikrein, or factor Xa
cleaves the Arg- 278 -Ile -279 bond of the proenzyme yielding two
polypeptide chains linked by disulfied bonds.The heavy chain
(A-chain) is derived from the amino-terminal, and has a MW of
40 kD, whereas the carboxy-terminal of the molecule comprises
the light chain (B-chain) and has a MW of 30 kD.(For review,
see Degen et al., 1986).
The catalytic site of tPA is located in the B-chain, and
is composed of His-322, Asp-371, and Ser-478 residues.The
heavy (A) chain consists of several structural domains and
shares a high degree of homology with other hemostatic
proteins.These domains are categorized as the fibronectin
finger domain, the epidermal growth factor (EGF) domain, and
the two kringle domains (I and II) (Gerard et al., 1986).
The nucleotide sequence of human tPA has been established,
and compared with urokinase; an evolutionary relationship of
the two human plasminogen activators is apparent (Degen et
al., 1986).The tPA gene is located on chromosome 8 in the
human and mouse (Rajput et al., 1985; Rajput et al., 1987).
Complementary DNA (cDNA) of human tPA had been constructed and14
several deletion mutants lacking specific functional domains
have been generated (Van Zonneveld et al., 1986).These
mutant tPAcDNA provide a powerful tool for studying the
physiological significance of the structural domains of tPA.
Tissue-type PA like uPA, catalyzes the conversion of
plasminogen to plasmin by cleaving the Arginyl-Valyl peptide
bond; however, a major difference between the two PA is the
high affinity of tPA for fibrin.In the absence of fibrin,
tPA is a poor plasminogen activator due to its low affinity
for the substrate, but the activity of tPA is strikingly
enhanced with fibrin.Fibrin provides a surface for tPA and
plasminogen yielding a ternary complex, thus enhancing
plasminogen activation (Hoylaerts et al., 1982).The binding
site of fibrin is located in the non-catalytic (A) chain.Van
Zonneveld and his colleagues (1986) used tPA mutants with
specific deletions of the heavy A-chain domains.They found
that the deletion of Kringle-II reduces plasminogen activation
by tPA in the presence of fibrin, while deletion of both
Finger and Kringle-II domains abolished the enzyme activity.
Therefore, the Finger domain and Kringle-II are responsible
for the interaction of tPA with fibrin.A very interesting
study was conducted by Dirk and his colleagues (1987) who used
a recombinant fusion molecule of the Finger domain of tPA with
scuPA, and demonstrated that the chimeric protein did not
acquire the fibrin affinity of tPA.Fusion of the amino-
terminal (A-chain) of tPA, which contains the structures
responsible for fibrin binding, with the carboxy-terminal of15
uPA, which contains the catalytic region of the molecule,
resulted in improve fibrin-mediated plasminogen activation
(Nelles et al., 1987).The results of these two studies
suggest that the functional domains of the heavy- (A) chain
may not be entirely independent.
Tissue-type PA is a glycoprotein containing approximately
7% carbohydrate.The carbohydrate moieties may not influence
the activity of the enzyme, however, glycosylation plays an
integral part in the transport of the protein out of the cell
(Hart and Rehemtulla, 1988).Hansen and coworkers (1988)
studied the role of Asn-linked oligosaccharide in non-
glycosylated and glycosylated tPA.The non-glycosylated tPA
showed higher fibrin binding, as well as greater fibrinolytic
potency than the glycosylated form.Their results indicated a
significant role for Asn-linked oligosaccharide in fibrin
binding and fibrinolytic potency of tPA.
Several reports have documented the existence of several
variants of native tPA.Two variants have been isolated from
the Bowes melanoma that differ by 3 kD from the native tPA.
This MW difference was localized in the amino-terminal of the
molecule.Differences in glycosylation pattern also lead to
the appearance of type I and II variants, with an apparent MW
difference of about 3 kD in the A-chain of tPA (Hart and
Rehemtulla, 1988; Grossbard, 1987).Immunoblot analysis,
using antibodies against tPA identified different types of tPA
variants (I to IV) in melanoma cell culture fluids, indicating16
that the composition of tPA is more complex and heterogenous
(Opdenakker et al., 1988).
Cell surface receptors, specific for tPA, have not been
identified as yet; however, the existence of an efficient
clearing system in the liver may suggest the presence of tPA
receptors.The rate and site of clearance of uPA is similar
to tPA.Urokinase receptors were identified in the liver, and
it is possible that a common receptor for both plasminogen
activators might exist in this organ (Hart and Rehemtulla,
1988).The clearance rate of a mutant tPA lacking the growth
factor domain was compared with normal tPA.Mutant tPA was
cleared much more slowly than normal tPA, indicating a role
for the growth factor domain in recognition of tPA by the
hepatic clearance system.Therefore, the growth factor domain
may constitute a determinant recognized by a receptor in the
liver (Browne et al., 1988).Two types of recognition sites
for tPA have been identified in the liver:a high affinity
specific tPA site on parenchymal cells and the mannose
receptor on endothelial cells which recognizes the
carbohydrate moiety of tPA.These sites are involved in the
clearance process of tPA from the circulation (Kuiper et al.,
1988).
3. Plasminogen activators inhibitors.
Inhibitors of PA can be divided into two classes.The
first class comprises the general protease inhibitors, such as the
macromolecular inhibitors, metal ions, and organic molecules.
These molecules are not specific for PA and their inhibitory17
effects may include a wide variety of plasma proteases.The second
class of PA inhibitors includes newly purified proteins that
exhibit high specificity toward PA.
a.Non-specific plasminogen activator inhibitors.
Diisopropyl fluorophosphate (DFP), a reagent which binds
to the active site of serine proteases, inhibits both uPA and
tPA as well as plasmin.While bovine pancreatic trypsin
inhibitor (Trasylol, aprotinin), soybean trypsin inhibitor,
and lima bean trypsin inhibitor exert a strong inhibitory
effect on plasmin, they fail to measurably inhibit PA.Zinc
is the most potent inhibitor of PA of all metal ions studied.
w-Aminocarboxylic acids affect PA-mediated fibrinolysis in a
complex manner.(For review, see Dano et al., 1985).
b.Specific plasminogen activator inhibitors (PAI).
Extracellular PA activity is mainly regulated by specific
high affinity inhibitors.Four distinct PA inhibitors (PAI)
have been identified:endothelial type PAI (PAI-1), placental
type PAI (PAI-2), urinary type PAI (PAI-3), and protease
nexin-1 (Laiho et al., 1987)1.
Plasminogen activator inhibitor-1 is the main PAI present
in plasma and serum.Plasminogen activator inhibitor-1
inhibits uPA, as well as tPA by forming stable complexes.
Plasminogen activator inhibitor-1 has been purified and
characterized, a cDNA has been cloned, and the amino acid
sequence deduced from the nucleotide sequence.These data
have clearly demonstrated that PAI-1 belongs to the18
superfamily of serpins (Lambers et al., 1987).Plasminogen
activator inhibitor-1 is a glycoprotein with a MW of 50 kD,
and is encoded by a gene located on the long arm of chromosome
7 (Mayer et al., 1988).Several human cells produce large
amounts of PAI-1 such as endothelial cells, platelets and
fibroblasts.Immunological studies using monoclonal
antibodies showed that PAI-1 from different cell types is
highly cross-reactive (Hart and Rehemtulla, 1988).
Plasminogen activator inhibitor-1 forms SDS-stable complexes
with both PA yielding proteinase-inhibitor complexes
detectable by zymography (Hart and Rehemtulla, 1988).
Plasminogen activator inhibitor-1 appears to exist in two
immunologically similar forms, an inherently active form and a
latent form which has no inhibitory activity.Treatment with
denaturants such as SDS or ammonium thiocyanate activate the
latent form.Cell-associated PAI-1 has similar molecular and
immunological characteristics with the latent form of PAI-1,
but is not affected by SDS treatment, suggesting that PAI-1,
synthesized as the active form, is a precursor to the latent
form (Eugene et al., 1987).Mimuro and coworkers (1987)
identified PAI-1 in the extracellular matrix (ECM) of cultured
bovine aortic-endothelial cells (BAE).They concluded that
PAI-1 is produced and released into the medium where it is
rapidly inactivated or into subendothelium where it binds to
ECM.The ECM-associated PAI-1 is active and stable,
indicating that ECM protects PAI-1 from inactivation.In a
subsequent study Mimuro and Loskutoff (1989a) demonstrated the19
presence of protease-sensitive structures on ECM of BAE that
bind active PAI-1 tightly and selectively, stabilizing PAI-1
against the spontaneous loss of activity.Bovine plasma
contains protein(s) that bind PAI-1 and prevent its
interaction with ECM.The PAI-1-binding protein has three
polypeptides with MW of 65 kD, 80 kD, and 57 kD, and share
immunological properties similar to vitronectin (Mimuro and
Loskutoff, 1989b).Another binding protein for PAI-1 was
isolated from human plasma, with a MW of 150 kD, and it
reacted only with the active PAI-1.This binding protein may
play an important role in regulating the activity of PAI-1
(Declerck et al., 1988).
Masson and Angles-Cano (1988) used radioisotropic and
spectrophotometric analysis to study the kinetics of
inhibition of tPA by active PAI-1 in homogeneous (plasma) and
heterogeneous (solid-phase fibrin) systems.The tissue-type
PA soluble phase is rapidly inhibited by PAI-1, whereas
fibrin-bound tPA is protected from inhibition.Furthermore,
PAI-1 interferes with the binding of fibrin to tPA in a
competitive manner.These data suggest the existence of an
equilibrium distribution of tPA between the amount of fibrin
generated and the concentration of circulating inhibitor,
which participate in a control mechanism for the fibrinolytic
activity of human plasma.
Plasminogen activator inhibitor-2 has been purified from
several cell types including human trophoblastic epithelium,
leukocyte-derived cell lines and fibrosarcoma cells.20
Plasminogen activator inhibitor-2 is immunologically distinct
from PAI-1.It exists in two different forms; a 47 kD, non-
glycosylated form and a 60 kO, glycosylated form, both sharing
identical inhibitory effects of PA.The cDNA of PAI-2 has
been cloned, and the amino acid sequence deduced from this
cDNA confirmed that this PAI belongs to the serpin family.
Plasminogen activator inhibitor-2 also can form an SDS-stable
complex with PA, and may be involved in regulating
extracellular PA activity (for review, see Kruithof, 1988;
Hart and Rehemtulla, 1988).
Plasminogen activator inhibitor-3 was first identified and
purified from human urine.It is a glycoprotein with an
apparent MW of 50 kD, and forms an SDS-stable complex with
mainly urokinase.Plasminogen activator inhibitor-3 is
antigenically distinct from PAI-1, PAI-2 and protease nexin.
Plasminogen activator inhibitor-3 purified from plasma has the
same MW, amino acid composition, and PA inhibitory effect as
the urinary protein.Kinetic analysis showed that PAI-3 has
an intermediate rate with urokinase and slow activity with tPA
(Stump et al., 1986).
Protease nexin (PN) is a glycoprotein with a MW of 47 kD.
It was first isolated from the conditioned medium of
fibroblasts and other cells.Protease nexin, unlike other
PAI, is not specific for PA; PN also binds to plasmin,
thrombin, and trypsin (Kruithof, 1988).21
II. Physiological Role of Plasminogen Activators
Plasminogen activators are found in a wide variety of normal and
neoplastic cells and tissues, suggesting these proteases have a
physiological role in several biological processes.Both enzymes have
been implicated in the degradation of extracellular matrices in several
normal and tumor-associated processes.It is beyond the scope of this
review to list and discuss all biological functions of PA, however, a
fairly thorough literature review will be provided for the role of PA in
various reproductive processes.
1. Fibrinolysis.
As stated by Ranby and Brandstrom (1988), "Fibrinolysis is an
integrated part of hemostasis, a collective name for the process
involved in keeping the circulatory tract intact yet free from
occlusive deposits."The role of PA has been most extensively
studied in fibrinolytic processes because of their potential use in
therapeutic treatment of some pathological conditions associated
with this process.Fibrin is the major component of clots and it
enhances the activity of tPA.The concentration of tPA in blood
increases after clot formation and tPA, not uPA, has been found in
the venous endothelial cells.These findings strongly point to
tPA, rather than uPA, as the key enzyme in the fibrinolytic system
(Dano et al., 1985).Besides tPA, the fibrinolytic system has
several components such as plasminogen, a2-AP, and PAI-1.The
control mechanism for tPA-mediated fibrinolysis is based on the
synthesis, release, and clearance of other fibrinolytic components
in the plasma (Ranby and Brandstrom, 1988).22
Circulating platelet aggregates are important in the formation
of thrombi.It has been shown that platelets provide a surface for
tPA thereby enhancing plasminogen activation.Plasmin, once
generated, degrades fibrin and promotes platelet disaggregation
(Schafer and Adelman, 1985; Deguchi and Shirakawa, 1988).Lascalzo
and Vaughan (1987) studied the disaggregation of human platelets by
tPA and found that fibrinogen induced platelet aggregation by
maintaining cohesion between platelet surfaces.Tissue-type PA
induced fibrinogenolysis through selective proteolysis by plasmin
and promoted platelet disaggregation.They concluded that tPA may
be important in vivo for lysis of thrombi containing both fibrin
and platelets.
Heparin and other sulphated polysaccharides may potentiate the
fibrinolytic activity by promoting the release of tPA from
endothelial cells.Heparin can bind to both plasminogen and PA
resulting in greater PA activity.Fears (1988) found that heparin
promoted the activity of PA and this effect was attenuated in the
presence of soluble fibrin.The binding site for heparin was
located on the A-chain of PA.If the effects of heparin occur in
vivo, then in the presence of heparin the enhancement effect of
fibrin on tPA will be diminished resulting in an increased systemic
activation of tPA.
2.Malignancy
The relationship between proteases and tumor cells was
reported as early as the first decade of this century.Several
investigators in that period noted that explants of cultured
cancerous tissue consistently caused dissolution of plasma clots23
(for a review, see Dano et al., 1985).This phenomenon was
explained a decade ago by Ossowski and her colleagues (1973).They
demonstrated that the transformation of normal fibroblasts by
oncogenic viruses caused an increase in extracellular proteolytic
activity due mainly to the release of PA.Ossowski and coworkers
(1973) compared the growth of normal and SV-40-transformed hamster
embryo fibroblasts in the presence and absence of plasminogen.
They discovered that the growth of normal and transformed cells
proceeded at the same rate in the absence or presence of
plasminogen, but the mobility and aggregation of transformed cell
were retarded in the absence of plasminogen.They concluded that
the fibrinolytic activity associated with malignancy was
responsible for cell aggregation and migration.The morphological
characteristics of transformed fibroblasts were altered by plasmin
and these changes did not develop in the presence of soybean
trypsin inhibitor.These data indicated the requirement of the
fibrinolytic system for the morphological changes accompanying
transformation of hamster fibroblasts (Ossowski et al., 1974).
Plasminogen activator activity was detected in many tumors
such as breast cancer, lung cancer, endometrial carcinoma, and
human prostatic cancer.Malignant tumors have a complex ECM
composed of collagen, soluble glycoproteins (such as fibronectin
and laminin) and fibrin.The interaction between malignant cells
and the extracellular matrix is important to the invasion and
metastatic processes.During metastasis, tumor cells first adhere
to ECM components, then initiate degradation with matrix and
migrate through the degraded products.High levels of PA activity24
have been localized extracellularly suggesting that fibrinolytic
activity is indeed involved in the degradation of extracellular
matrix surrounding cancerous cells, thus facilitating their
invasiveness and metastasis.The best support for this hypothesis
comes from the inhibition of metastasis of human HEP-3 tumor in
chicken embryos by antibodies raised against uPA (Dano et al.,
1985).
Christman and coworkers (1975) used Brad-U sensitive melanoma
B-16 to study the functional relationship between expression of PA
and tumorigenicity.Melanoma cells produced appreciable amounts of
PA in the absence of Brad-U.However, tumorigenicity and the
expression of PA reversibly and concurrently disappeared when
melanoma cells were grown in the presence of this drug.The
precise mechanism by which Brad-U suppresses PA and tumorigenicity
in these cells is not known.
The relationship between brain tumors and PA has not been
fully investigated.Extracts of human brain tumors induce
fibrinolysis.Varani and coworkers (1987) showed that different
types of human brain tumor produced high levels of PA.These
enzymes were capable of degrading ECM and influenced tumor-cell
adhesion to ECM moieties.Specific MW patterns ranging from 36 kD
to 100 kD were identified in five brain tumors suggesting a cell-
specific origin of various PA forms.Malignant tumors showed a
greater PA activity and a larger number of MW patterns when
compared to normal brain tissues and benign tumors.Exposing tumor
cells to radiation significantly reduced PA activity.Brain edema,25
associated with brain tumors, correlated slightly with PA activity
(Sawaya et al., 1988).
3. Inflammatory reactions.
Monocytes and macrophages are the major phagocytes
participating in inflammatory reactions.These cells produce and
release PA.Inflammatory agents enhance PA production, while anti-
inflammatory agents, such as glucocorticoids suppress it.The
physiological role of phagocytic PA is not fully understood,
however, it may be involved in the proteolytic digestion of ECM
necessary for these cells to migrate (Vassalli et al., 1984).
Plasminogen activator secretion is a differentiation-linked
property, with tPA being produced by primitive cells, such as
macrophage progenitors, and uPA by more differentiated cells, like
neutrophils and macrophages (Wilson and Francis, 1987).
Peritoneal macrophages, induced with inflammatory agents such
as endotoxins, produced significant amounts of PA, whereas non-
activated macrophages do not.Differences in PA production by the
two cell populations may be due to cell age (Unkeless et al.,
1974).Vassalli and coworkers (1974) proposed the following
hypothesis to explain the relevance of PA to macrophages and
inflammation.They suggested that macrophage precursors require an
enzymatic mechanism to hydrolyze some of the supporting structures
of blood vessels and allow their migration from the bone marrow to
the circulation and from the circulation to the peritoneal cavity.
Plasmin generated by PA released from macrophages will provide a
localized proteolysis of the connective tissue structures of small26
vessels, thereby facilitating the migration between various body
compartments (Vassalli et al., 1976).
A recent study by Gudewicz and Gibola (1987) examined the
effect of PA on the migration of human neutrophils.Their results
indicated that human uPA exhibited chemoattractant activity in
human neutrophils.Incubation of uPA with anti-uPA antibody
completely abolished the chemotactic activity of uPA.Human tPA,
with similar concentration as uPA, showed no chemotactic activity.
They concluded that the chemotactic-stimulating activity of uPA
plays a role in recruiting circulating phagocytes to the
inflammatory site.
4. Nervous system.
Cell migration is necessary for the development and
maintenance of several parts of the nervous system.Plasminogen
activators have been identified in various neural cells, including
Schwann cells, astrocytes, neuroblastoma cells, and sensory
neurons.Plasminogen activator activity has been implicated in
granule cell migration in the cerebellum, Schwann cell
proliferation and migration, and memory storage (for review, see
Pittman, 1985; Krystosek et al., 1988).
Pittman (1985) studied the patterns and properties of PA
released by neurons from neonatal rat superior cervical, dorsal
root, and trigeminal ganglia.Pittman (1985) found that neurons
spontaneously released PA with similar immunological and
physiochemical properties as uPA.Most PA was released by distal
processes and/or growth cones suggesting that this enzyme may
regulate growth cone function.Verrall and Seeds (1988) found that27
neonatal mouse cerebellar cells release mainly tPA.Fibrin
overlays localized PA to granule neurons, and the activity of this
enzyme was blocked by anti-tPA antibodies.Verrall and Seeds
(1988) also demonstrated that granule cell-associated tPA can be
displaced by pH shock and exogenous mouse-tPA binds specifically to
granule neurons.Accordingly, Verrall and Seeds (1988) claimed
that these results supported the presence of a specific receptor
for tPA on granule neurons where the enzyme retained its activity
and may function in cell migration.
Neonatal rat dorsal root ganglia release both uPA and tPA.
Urokinase-type PA is secreted by neurons while tPA is released by
Schwann cells.Only uPA was shown to have a mitogenic effect on
astrocytes and Schwann cells.This effect was observed in serum-
free medium without plasminogen, suggesting the presence of an
unknown substrate for PA other than plasminogen (Baron-Van
Evercooren et al., 1987).
5.Other functions of PA.
Urokinase-type PA has been implicated in the migration and
tissue remodeling in the bursa of Fabricicus.The production of PA
by pancreatic islets of Langerhans has been correlated with the
conversion of proinsulin to insulin.A similar correlation was
found between PA and anterior pituitary hormones, suggesting that
PA is involved in prohormone processing.Furthermore, PA have been
related to angiogenesis, thymocyte maturation, development of
neonatal skeletal muscles, and many other functions (Dano et al.,
1985; Hantai et al., 1989; Fulton and Hart, 1987).28
6.Reproduction.
Extracellular proteolysis and tissue degradation are involved
in several reproductive phenomena.The distribution of PA in many
reproductive organs is well documented and numerous studies have
been conducted to further investigate the role of PA in male and
female reproduction.The review of this subject will be subdivided
into several categories describing the role of PA in female
reproduction, male reproduction, and embryogenesis.
a.Female reproduction.
Involution of the mammary glands is characterized by
considerable tissue degradation and remodeling.A strong
correlation has been reported between mammary gland involution
in mice and the activity of PA.Plasminogen activator
activity in mammary glands tissue is inhibited in the presence
of combinations of lactogenic hormones such as insulin,
prolactin and hydrocortisone.Only uPA was identified in
tissue extracts obtained from involuting mammary gland.
Histological changes of mammary tissue during involution have
some resemblance to the changes observed in metastatic growth
of cancerous tissues.All these findings clearly demonstrate
the importance of PA during involution of mammary glands which
is necessary for preparing the udder for the next lactation
(for review, see Dano et al., 1985).
Ovulation in mammals is a unique biological phenomenon
because it requires the disruption of a healthy tissue at the
surface of the ovary.This process involves many
morphological changes at the site of rupture such as (1)29
disruption of the dense layers of connective tissue
surrounding the mature follicle, (2) extravasation of blood,
(3) release of the ovum, (4) subsequent formation of a blood
clot, and (5) wound healing (Espey, 1975).The changes that
accompany ovulation necessitate the existence of highly
efficient proteolytic and fibrinolytic mechanisms in order for
these changes to occur.Plasminogen activators have been
detected in large quantities during the ovulatory process
indicating a close correlation between ovulation and PA.
Several workers studied the involvement of PA in the
degradation of the follicular wall during ovulation.A close
temporal correlation has been found between PA activity and
the disruption of rat granulosa cells.Low PA activity was
shown to be associated with granulosa cells obtained from
immature animals.Comparative data have shown that granulosa
cells from preovulatory follicles have high PA activity, while
granulosa cells isolated from nonpreovulatory follicles in the
same ovary exhibited low PA activity.Plasminogen, PA, and
PAI have been detected in copious amounts in the follicular
fluids.The activation of follicular plasminogen to plasmin
by PA decreases the tensile strength of the follicular wall.
The above findings led to the conclusion that PA plays a
significant role during mammalian ovulation (Beers, 1975;
Beers et al., 1975; Strickland and Beers, 1976).
Although the biochemical basis of ovulation is not firmly
established, the critical role of gonadotropins and enzymatic
activity are well documented.Beers and coworkers (1975)30
attempted to elucidate the enzymatic basis of the events
preceding ovulation.They proposed that granulosa cells
elaborate increasing amounts of PA in response to the
increased levels of circulating LH.This enzyme acts on
follicular plasminogen, generating plasmin within the
follicular wall.Plasmin, in turn, activates another
protease, collagenase, which nicks the collagen helices and
allows further degradation of collagen and the follicular wall
by nonspecific proteases.The enzymatic degradation of the
basement membrane will lead to the disruption of follicular
integrity necessary for the release of the ovum.The ability
of several inhibitors of PA and collagenase to block ovulation
supports this hypothesis.Treatment of proestrous rats with
E-amino-caproic acid (CA) and benzamidine, inhibitors of
serine proteases, including PA and plasmin, blocked ovulation
and collagenolysis.Serine protease inhibitors significantly
inhibited ovulation and collagenolysis only during the first
two hours after hCG administration (Reich et al., 1985).By
contrast, inhibition of ovulation and collagenolysis by
collagenase inhibitor such as cysteine, was effective even
when administered 7 h after hCG.These temporal relations
support the role of PA and plasmin in the early events of the
ovulatory process (Reich et al., 1985).
Gonadotropins, having a central role in ovulation, have
been identified as the major controlling factor for
follicular-associated PA activity (Beers et al., 1975).
Gonadotropins stimulate the release of PA from inactive31
ovarian granulosa cells in a time- and dose-dependent fashion.
Follicle-stimulating hormone (FSH) was more effective in
inducing PA activity than luteinizing hormone (LH) and
prostaglandins E1 and E2 and cAMP effectively stimulated the
production of PA by granulosa cells (Strickland and Beers,
1976).Canipari and Strickland (1986) compared the effect of
FSH and LH on granulosa cells in culture and found that both
hormones stimulated PA secretion; however, a lag phase in the
pattern of enzyme secretion was noted with LH.They suggested
that LH induction of PA is mediated by prostaglandins (PG).
Evidence to support their claim came from the observation that
LH stimulates PG synthesis and that treatment with PG
inhibitors such as indomethacin suppresses PA secretion.
These results may explain the ability of indomethacin to
inhibit ovulation.The above findings contrasted the results
presented by Shimada and coworkers (1983).They found that PG
were not involved in the synthesis of PA in the rat ovary
during the preovulatory period.This contrast can be
explained by the difference in tissue extracts and analytical
methods employed in these studies.
Two types of PA (uPA and tPA) have been demonstrated in
granulosa cells.Liu and Hsueh (1987) studied the molecular
patterns and secretion of PA in rat cumulus-oocyte complexes.
They found that both uPA and tPA were present in the cumulus-
oocyte complexes, while denuded oocytes contained only tPA.
Human chorionic gonadotropin (hCG) treatment induced a time-
dependent increase in tPA activity in both cumulus-oocyte32
complexes and denuded oocytes.Urokinase-type PA activity was
also detected after hCG injection.Morphological signs of
cumulus cell expansion and dispersion have been observed after
the increase in oocyte tPA activity.They concluded that
oocyte tPA may be involved in oocyte maturation and cumulus
cell expansion and dispersion.Immunohistochemical studies
supported the conclusion that tPA induction by gonadotropin is
correlated with follicle rupture (Liu et al., 1987).
Substantial evidence for the role of tPA in ovulation was
recently presented by Tsafriri and colleagues (1989) who
examined the direct relationship between PA and ovulation
using a2-AP and an antibody raised against tPA.They found
that anti-tPA and a2-AP significantly inhibited ovulation only
when injected at the time of hCG treatment.These results
confirmed the earlier finding that PA participates in the
early follicular events of the ovulatory process.
Species differences with regard to the types of PA
secreted by granulosa cells were reported.While rat
granulosa cells secrete mainly tPA, mouse cells secret
predominantly uPA.Similar differences between mouse and rat
PA were observed in the follicular fluids.Mouse uPA
production in granulosa cells is stimulated by gonadotropins,
prostaglandin E2, and cAMP (Canipari et al., 1987).The
follicular wall and follicular fluid obtained from the sow
were shown to have both uPA and tPA.The activity of these
enzymes exhibited the highest level at the time of ovulation,33
and specifically in the area of the follicular rupture
(Smokovitis et al., 1988).
b.Male reproduction.
Sertoli cells are found along the basement membrane of the
seminiferous tubules.These cells have a central role in the
maintenance of spermatogenesis.They form the major component
of the blood-testis barrier, which is required for the
maintenance of the microenvironment necessary for developing
germinal cells.Sertoli cells have been shown to secrete
several proteins including PA in response to hormonal
stimulation (Fritz et al., 1976; Lacroix et al., 1981).The
morphological development of spermatogonium to spermatozoa
occurs in a cycle known as the cycle of the seminiferous
epithelium.Fourteen successive stages have been identified
in the rat cycle (Clermont, 1972).
Lacroix and coworkers (1981) studied PA secretion in
tubule segments at different stages of the cycle of the
seminiferous epithelium of the rat.Plasminogen activators
were observed to increase 100-fold at stages VII and VIII of
the cycle.These stages are the regions in which spermiation,
and movement of Sertoli cell cytoplasmic processes around
leptotene spermatocytes take place.They concluded that PA
was involved in the localized restructuring of the
seminiferous tubule which allows the translocation of
spermatocytes in meiosis into the adluminal compartment.
Primary cultures of immature rat Sertoli cells maintained
under basal conditions secrete predominantly uPA; however,34
these cultures predominantly produce tPA when stimulated with
FSH or cAMP.A similar trend, with regard to types of PA, has
been observed at defined stages of the cycle of the
seminiferous epithelium.Tubule segments induced by FSH
showed an increased secretion of PA, predominantly tPA.
Nevertheless, higher levels of uPA were observed particularly
during stages VII and VIII.These observations further
confirmed the significant role of PA in the restructuring of
the seminiferous tubules during spermatogenesis (Hettle et
al., 1986).
In addition to the secreted forms of PA, cultured Sertoli
cells expressed a membrane-associated PA with a molecular
weight of 38-40 kD.The membrane-associated PA may function
in the restructuring of discrete membrane components at the
cellular interface (Marzowski et al., 1985).Immunohisto-
chemical studies show the presence of uPA exclusively at
stages VII and VIII in Sertoli cells.On the other hand, tPA
immunoreactivity was maximal during stages IX-XIII.These
studies identified uPA as the main PA in the process of
seminiferous tubule restructuring (Vihko et al., 1988).
Coombs and coworkers (1988) used monospecific antibodies to
determine the type of PA produced by bovine Sertoli cells.In
contrast to the rat, bovine Sertoli cells produce only tPA,
indicating a species difference between rat and bovine cells.
c.Embryo development.
The role of PA in oocyte physiology has been explored by
several workers.Huarte and coworkers (1985, 1987) found that35
ovulated rat and mouse secondary oocytes contain tPA, whereas
primary oocytes isolated from ovaries do not.Tissue-type PA
in primary oocytes matured in vitro became detectable 5 h
after germinal vesicle breakdown, and this induction was
blocked by protein translational inhibitors and cAMP.These
results suggest that tPA mRNA is present in primary oocytes in
a dormant state.Translation of tPA mRNA is triggered upon
resumption of meiosis, and is accompanied by an elongation of
the poly (A) tail.Finally, they postulated that PA may
participate in early biochemical events such as fertilization,
proacrosin activation and the zona reaction that blocks
polyspermy.
Liedholm and Astedt (1975) provided the first evidence of
the crucial role of PA in the developing embryo.Their
results demonstrated that the fibrinolytic activity of the
fertilized rat ova was high during tubal passage but this
activity disappeared during implantation.The high
fibrinolytic activity during tubal passage may help to prevent
the adhesion of the embryo to the tubal wall.In contrast,
the low fibrinolytic activity during implantation may be
required for embryo attachment to the endometrium.
The extensive tissue remodeling of the endometrium and
embryonic cell migration during the early periods of embryo
development demonstrate the importance of PA.Strickland and
coworkers (1976) examined the production of PA during the
early stages of mouse embryo development.Plasminogen
activator was produced by cultured blastocysts in a biphasic36
pattern.In the first phase, enzyme activity started at the
sixth day and reached a maximum at the eighth or ninth day,
then started to decline.In the second phase, PA activity
started at the eleventh day, persisted until the fifteenth day
and was 5-fold higher than the activity exhibited during the
first phase.This temporal pattern of PA production suggests
the participation of at least two cell populations.To
identify the source of PA, they separated the blastocyst into
trophoblast which constitutes the outer cellular layer and the
inner cell mass (ICM).They found that trophoblast cells
contributed to PA production during the first phase.The
enzymatic activity of trophoblast was correlated with the
invasive capacity of these cells suggesting that PA
participated in embryo implantation.On the other hand, the
second phase of PA production was correlated with the
differentiation of parietal endoderm from ICM.The migratory
properties of parietal cells implicate PA in cellular
migration and tissue remodeling.The overall conclusion of
this study was that PA may play a role in embryo
morphogenesis.Plasminogen activator production by parietal
endoderm led Sherman and coworkers (1976) to suggest the
possibility of using PA as a biochemical marker to distinguish
and identify parietal endoderm in the early embryo.
Bode and Dziadek (1979) further investigated the types of
embryonic cells which could synthesize and release PA.They
dissected midgestation mouse embryos into their major
component tissues.Their results demonstrated that the37
development of mouse embryos from the seventh to the tenth day
of gestation was associated with a progressive increase in PA
secretion in different tissues.By day 10 all tissues tested
(parietal endoderm, visceral yolk sac endoderm, mesoderm, and
amnion) secreted PA.The widespread pattern of embryonic PA
restrict its usefulness as a tissue-specific biochemical
marker.Nevertheless, the presence of this protease in
various parts of the midgestation embryo indicates an
important function in embryonic growth.
Sherman (1980) compared the fibrinolytic activity in zona-
enclosed embryos, empty zonae, zona-stripped embryos, and
cultured embryos.He found that the fibrinolytic activity of
preimplantation mouse embryos was restricted to the zona
pellucida, indicating that mouse embryos at this stage do not
secrete PA.Furthermore, he showed that this enzyme was not
involved in either hatching from the zona pellucida or the
acquisition of trophoblast adhesiveness.However, the
observations that blastocysts produce PA at the same time when
trophoblast cells acquire their migratory properties is
consistent with the view that PA plays a pivotal role in
trophoblast invasiveness during implantation.
Two types of PA have been identified in mouse embryos.
The parietal endoderm PA has a predominant MW of 79 kD and
this enzyme is inhibited only by antibodies raised against t-
PA.The visceral endoderm and extraembryonic mesoderm PA have
MW of 48 kD and are inactivated by anti-uPA antibodies.The
specific cell-associated PA can be used as a diagnostic marker38
to study parietal endoderm differentiation during the early
stages of mouse embryogenesis (Marotti et al., 1982).On the
other hand, cultured human cytotrophoblasts synthesize and
secrete uPA which may account for the high capacity of these
cells to degrade extracellular matrix proteins (Queenan et
al., 1987).
The attachment of the porcine embryo to the endometrium
does not involve a high degree of trophoblast invasion;
however, pig trophoblast becomes highly invasive when
ectopically transplanted to the spleen or lens capsule
(Samuel, 1971).Mullins and coworkers (1980) examined the
absence of the invasive characteristic of porcine blastocysts
during the period of uterine attachment.Plasminogen
activator activity in the uterine flushings was high during
the early and late stages of the estrous cycle.In contrast,
the activity of the enzyme became low during the luteal phase
and at day 12 of gestation.A time-dependent increase in PA
activity was observed when blastocysts were grown in culture,
indicating that the enzyme activity was inhibited in vivo.A
hormonally-induced protease inhibitor was found in the
flushings of cycling gilts during the luteal phase and of
progesterone-treated ovariectomized gilts.They concluded
that the lack of the invasiveness in porcine blastocyst may
have been due to the secretion of a progesterone-induced
inhibitor by the uterus.The potential ability of porcine
blastocysts to produce PA was confirmed by Fazleabas and
coworkers (1983).A biphasic pattern of PA production by Day-39
10 and Day-16-cultured porcine blastocysts was detected.The
first phase (Days 10-12) coincided with the period of tissue
remodeling, while the second phase (Days 14-16) occurred
during the stage of tissue proliferation.Moreover, the
release of protease inhibitor by pregnant animals rose to ]-
fold between days 10-12.A similar effect can be initiated in
cycling gilts by a single injection of estradiol valerate on
Day 11 of the estrous cycle.Thus, it is reasonable to
conclude that the initiation of estrogen production by
elongating pig blastocyst triggers the release of plasmin
inhibitor by the endometrium (Fazleabas et al., 1983).
Plasminogen has been detected in uterine flushings from
both the pig and mouse and the source of this zymogen is
probably the circulation (Fazleabas et al., 1983; Finlay et
al., 1983).The ability of the embryo to produce PA, which in
turn converts plasminogen to plasmin, suggests that the
fibrinolytic system may be involved in the regulation of
various aspects of early embryo development.Menino and
O'Claray (1986) compared the development of mouse embryos in
media supplemented with plasmin or plasminogen to media
lacking these enzymes or containing trypsin and pronase.More
embryos developed to blastocysts, and escaped from the zona
pellucida in media supplemented with plasmin or plasminogen.
Furthermore, the incidence of attachment to the substratum and
trophoblastic growth was greater in the presence of plasmin
and plasminogen.Therefore, they concluded that plasmin and40
plasminogen may exert a trophic effect during the early stages
of embryonic development.
Our laboratory has been inspired by the numerous reports
associating PA with early embryo development.Several studies
have been designed to characterize PA production, and to
elucidate the function of this enzyme in different farm animal
species.Menino and Williams (1987) evaluated plasminogen
activation by cultured bovine embryos.They found that
plasminogen had no effect on hatching rate, but high
concentrations of this zymogen accelerated hatching.The
production of PA was low for the first two days of culture,
increased between Days 2 and 5, and plateaued thereafter.
They speculated that plasminogen activation by the bovine
blastocyst may facilitate hatching by inducing a sublysis of
the zona pellucida.However, data from zona dissolution
experiments showed that plasminogen had no effect on bovine
zona pellucida solubility (Menino and Williams, unpublished
results).The latter finding may indicate that plasminogen is
not involved in hatching.Kaaekuahiwi and Menino (1989)
demonstrated that PA activity was positively correlated with
the viability of bovine embryos.Dyk and Menino (unpublished
data) found that bovine hatched blastocysts produce two types
of PA associated with the trophoblast, an uPA (MW=49 kD) and a
tPA (MW=85 kD).
Cultured ovine embryos produced PA at Day 5; however,
enzyme activity was first low, then peaked approximately 2-3
days prior to hatching, and remained high throughout the41
culture period.Unlike the cow, increasing levels of
plasminogen in the culture media increased both the hatching
rate and the solubility of the ovine zona pellucida.These
findings support the hypothesis which implicates plasminogen
and PA in embryo hatching (Menino et al., 1989).Plasminogen
has also been shown to stimulate cell division and hatching in
cultured rabbit embryos (Grobner and Menino, unpublished
results).
III. Regulation of Plasminogen Activator Activity
Total PA activity is determined by a balanced interaction between
plasminogen, PA, and their inhibitors.Regulation of the extracellular
proteolytic activity of PA occurs at various levels:(1)
transcriptional, (2) translational, (3) cellular release of the
proenzyme, (4) activation of proenzyme to active PA, (5) plasminogen
activation, and (6) proteolytic activity of plasmin (Dano et al., 1985).
Several hormones and factors have been shown to modulate PA activity
either directly or indirectly by affecting the availability of the
substrate or inducing protease inhibitors.Some of the well-
characterized PA modulators will be discussed here with a brief
description of the mechanisms by which they exert their action.
1.Gonadotropins and cyclic AMP.
Gonadotropins stimulate the activity of PA in rat granulosa
cells (Beers et al., 1975; Strickland and Beers, 1976; Shimada et
al., 1983; Espey et al., 1985; Reich et al., 1985; Canipari and
Strickland, 1986; Canipari et al., 1987; Ny et al., 1987; Liu et
al., 1987), rat cumulus-oocyte complexes (Liu and Hsueh, 1987; Liu42
et al., 1987; Ny et al., 1987), cultured human cytotrophoblasts
(Queenan et al., 1987), rat Sertoli cells (Lacroix et al., 1981;
Marzowski et al., 1985; Nettle et al., 1986; Guillou et al., 1987;
Bergh et al., 1987; Nettle et al., 1988), and bovine Sertoli cells
(Jenkins et al., 1988).
The stimulatory effect of gonadotropins on PA activity was
mimicked by cAMP in most of these studies suggesting that
gonadotropin action is mediated by cAMP.This is in agreement with
the generally accepted hypothesis that cAMP mediates the response
of many polypeptide hormones.The increase of cellular cAMP can
increase de novo synthesis of PA by promoting transcription of the
PA gene (Nagamine et al., 1983).A parallel increase in uPA
synthesis and uPA mRNA was observed in cAMP-treated human
cytotrophoblasts (Queenan et al., 1987).
The molecular mechanism of PA gene regulation by cAMP is not
yet known; however, the gene regulatory effect of cAMP is usually
mediated by cAMP-dependent protein kinase A (cAMP-PK-A).These
enzymes are made up of two regulatory (R) and two catalytic (C)
subunits.The binding of cAMP to the regulatory subunits results
in the release and subsequent activation of the catalytic subunits.
Three hypothetical mechanisms for intracellular transmission of
cAMP-mediated gene regulatory signals have been presented by Nigg
and coworkers (1988).Pathway I postulates that PK-A regulatory
subunits, activated by bound cAMP, translocate to the nucleus and
interact with cis-regulatory DNA sequences of the PA gene.Pathway
II postulates that transcriptional activation involves the
phosphorylation of trans-acting-regulatory factor by the activated43
catalytic subunit (C) of PK-A.Pathway III postulates that cAMP-
dependent phosphorylation of a cytoplasmic mediator will trigger
cascade events leading to the transcriptional signal.
Immunocytochemical analysis of subcellular distribution of PK-A
subunits indicates that the second pathway is indeed the mechanism
by which cAMP regulates and induces the transcription of the PA
gene (Nigg et al., 1988).Jans and coworkers (1987) evaluated the
induction of uPA by reagents activating cAMP-PK-A.Their results
excluded the involvement of the regulatory (R) subunit of cAMP-PK-A
in promoting gene transcription.They suggested that the cAMP-PK-A
catalytic subunit was the primary regulator for PA gene expression.
Degen and his colleagues (1987) isolated the complete nucleotide
sequence of the murine uPA gene and identified a short sequence
homologous to the proposed 5'-flanking cis-acting regulatory
elements which mediate cAMP induction of gene expression.
Gonadotropin-releasing hormone (GnRH) induces the production
of tPA and tPA mRNA by cultured granulosa cells and cumulus-oocyte
complexes.These effects were inhibited by co-treatment with a
GnRH antagonist suggesting the presence of steriospecific receptors
in these cells.Moreover, the GnRH stimulatory effect was mimicked
by phorbol myristate acetate (PMA), a stimulator of protein kinase
C.These results indicate that the GnRH effect may be mediated by
specific receptors through the activation of the protein kinase C
pathway.This is in contrast to other gonadotropins which mediate
their effects by elevating cellular cAMP and activating the protein
kinase A pathway (Ny et al., 1987).44
2.Ovarian steroids.
Estrogen stimulated production of PA in human breast carcinoma
cell lines MCF-7 (Dickerman et al., 1989), and ZR-75-1 (Huff and
Lipmann, 1984).The enhancement of PA activity in MCF-7 cell lines
was suppressed by 2,3,7,8,-tetrachlorodibenzo-p-dioxin (Gierthy et
al., 1987).In addition, estrogen stimulated the uptake of
plasminogen by the mouse uterus (Finlay et al., 1983); however, PA
activity of mouse uterine fluid was suppressed by estrogen (Harpel
et al., 1966, 1967).Estrogen has been shown to induce the
production of a plasmin-inhibitor by pig endometrium during the
period of implantation, thus preventing the proteolytic degradation
of the uterine wall (Fazleabas et al., 1983).
Progesterone has been reported to induce protease inhibitors
in mouse (Harpel et al., 1966) and pig uteri (Mullins et al., 1980;
Fazleabas et al., 1982).The progesterone-induced inhibitor is
secreted during the luteal phase and Day 12 of pregnancy which
coincide with the period of embryo attachment to the endometrium.
Steroid hormones are generally believed to influence protein
synthesis by changing the rate of gene transcription.Actinomycin-
D blocked the induction of PA by estrogen from MCF-7 breast
carcinoma cell line.This conforms with the assumption that
estrogen induction of PA requires de novo synthesis of mRNA (Dano
et al., 1985).
3.Glucocorticoids.
Glucocorticoids have been reported to suppress the activity of
PA in a variety of cultured cells and tissues, including rat
granulosa cells (Harlow et al., 1987), bovine Sertoli cells (Coombs45
and Jenkins, 1988), primary cultures of rat hepatocytes (Heaton et
al., 1989), rat hepatoma cells (Gelehrter et al., 1987; Heaton and
Gelehrter, 1989), human tumor-derived cells (Roblin and Young,
1980; Andreasen et al., 1986; Amin et al., 1987; Andreasen et al.,
1987; Rehemtulla and Hart, 1987), and murine macrophages (Vassalli
et al., 1976; Chow et al., 1987).Glucocorticoids had no effect on
PA activity expressed by human melanoma cells (Roblin and Young,
1980).
There are three possible mechanisms by which glucocorticoids
suppress PA activity.First, glucocorticoids can operate at the
transcriptional and/or translational levels to suppress de novo
synthesis of PA.Second, glucocorticoids could reduce cellular PA
activity by inducing synthesis and release of protease inhibitors.
Finally, glucocorticoids might stimulate the cellular inactivation
and degradation of PA.
Harlow and coworkers (1987) reported that cortexolone, a
glucocorticoid antagonist, significantly ameliorated the
suppressive effect of glucocorticoids on PA secretion by rat
granulosa cells.Furthermore, they observed that a time delay was
required for glucocorticoids to take effect.Collectively, these
data suggest that glucocorticoids bind to specific receptors and
induce the synthesis of a protein with anti-protease activity
(possibly a PAI).Coombs and Jenkins (1988) characterized a PAI
induced by glucocorticoids in immature bovine Sertoli cells.This
novel inhibitor has an apparent MW of 49 kD, and shares antigenic
determinants with placental and macrophage PAI and fibroblast
protease nexin.46
Incubation of HTC rat hepatoma cells with the synthetic
glucocorticoid dexamethasone induced a rapid 90% inhibition of PA
activity and the concomitant appearance of PAI-1.Although
immunologic and biochemical studies showed that dexamethasone
treatment of HTC cells increased the amount of PAI 4- to 5-fold,
this treatment did not decrease cellular levels of PA.These
results reveal that glucocorticoid inhibition of PA activity in HTC
cells is not due to a decrease in the amount of PA but is primarily
due to the induction of PAI-1 (Cwikel et al., 1984; Gelehrter et
al., 1987).Plasminogen activator inhibitor-1 mRNA has been shown
to increase 4- to 5-fold when HTC cells were incubated with
dexamethasone.Cycloheximide, a protein synthesis inhibitor,
neither affected the accumulation of PAI-1 mRNA nor blocked its
induction by dexamethasone; however, induction was blocked by
actinomycin-D.Accordingly, the dexamethasone-induced increases in
HTC cell PAI-1 activity are the result of a direct effect on the
accumulation of PAI-1 mRNA (Heaton and Gelehrter, 1989).
Therefore, in rat HTC hepatoma cells, glucocorticoid inhibition of
PA activity is mediated at the molecular level by the induction of
PAI-1 gene expression rather than by the suppression of PA gene
expression.
Glucocorticoid inhibition of PA activity in rat hepatocytes,
however, is different from HTC hepatoma cells.Heaton and
coworkers (1989) studied the effect of dexamethasone and cAMP on PA
activity in primary cultures of rat hepatocytes.Incubation of
these cells with cAMP resulted in a 4-fold increase in PA activity,
whereas dexamethasone caused more than a 90% decrease in PA47
activity.Moreover, dexamethasone completely abolished the cAMP
effect and significantly decreased PA activity.Both cAMP and
dexamethasone induced the production of PAI-1.Hepatocyte PAI-1
mRNA levels were increased 4-fold by a combination of cAMP +
dexamethasone.The authors concluded that cAMP induced PA activity
directly by increasing PA mRNA accumulation.Dexamethasone,
however, caused a decrease in PA activity by both decreasing PA
mRNA and increasing PAI-1 mRNA.The primary effects of both agents
are believed to be related to gene transcription or mRNA stability.
4.Phorbol esters.
Phorbol esters have been reported to enhance plasminogen
activator production by a human melanoma cell line (Bowe)
(Opdenakker et al., 1983), human bladder carcinoma cells T-24
(Rehemtulla and Hart, 1987) and human endothelial cells (Santell
and Levin, 1988).In contrast, phorbol esters stimulated secretion
of PAI in human rhabdomyosarcoma (RD) cell line (Meyer et al.,
1988), mouse L-cells (Rehemtulla et al., 1987), and mouse resident
peritoneal macrophages (Wohlwend et al., 1987).Phorbol esters
were found to be without effect on PA activity in explants of
involuting murine mammary gland and in primary cultures of rat
pituitary cells (Dano et al., 1985).
The effect of phorbol esters on PA production is probably
mediated through activation of the protein kinase C pathway, which
has been identified as the primary cellular receptor for phorbol
esters.The enhanced production of PA by Bowe melanoma cells after
treatment with 12-0-tetradecanoylphorbol-13-acetate is accompanied
by a concomitant increase in the cellular level of PA mRNA.This48
suggests that phorbol esters participate, either directly or
indirectly, in inducing PA gene transcription (Opdenakker et al.,
1983).In addition to PA, endothelial cells release PAI-1, which
may regulate PA activity in these cells.Santell and Levin (1988)
investigated the effects of phorbol esters and cAMP on PA and PAI-1
secretion.Phorbol esters induced a time- and dose-dependent
increase in PA release from endothelial cells, while cAMP had no
significant effect.However, cAMP elevation increases phorbol
ester-stimulated PA release 6-fold, and decreases secretion of PAI-
1 by 30-40%.The inhibitory effect on PAI-1 secretion is directly
attributed to the increased cAMP levels.They concluded that
phorbol esters and cAMP acted coordinately to regulate and modify
PA and PAI-1 secretion from endothelial cells.
The mechanisms by which phorbol esters enhanced the secretion
of PAI-1 in some cells have been evaluated by several workers.
Meyer and coworkers (1988) used an enzyme-linked immunosorbent
assay (ELISA) to study the effect of phorbol 12-myristate 13-
acetate on PA secretion in human RD cells.They found that PMA
caused a 10-fold increase in PAI-1.The enhancement of PAI-1
secretion was accompanied by a 20-fold increase in the cellular
level of PAI-1 mRNA and more than a 5-fold increase in PAI-1 gene
transcription rate.Cycloheximide treatment did not suppress the
PMA-stimulated increase of PAI-1 mRNA indicating that protein
synthesis was not required for the PMA effect.Co-administration
of cycloheximide with PMA resulted in a strong increase in PAI-1
mRNA levels, which indicated that a short-lived protein negatively
regulates the level of PAI-1 mRNA either by suppressing PAI-1 gene49
transcription or by destabilizing the mRNA.It is noteworthy to
indicate that PMA in this study also stimulated PA production by RD
cells, but with a smaller magnitude than the stimulation of PAI-1.
The overall PA activity in RD cells was not affected by the PMA-
stimulated increase in PAI-1.This paradoxical phenomenon might be
explained by the difference in spatial ultrastructural
localizations of PA and PAI-1.This explanation was confirmed by
the finding that PA is localized mostly to cell-cell and focal
contacts, whereas PAI-I is uniformly deposited on the cell
substratum.The distinct localization of the enzyme and its
inhibitor saves the enzyme activity for the time when it is
required (Pollanen et al., 1988).
5.Retinoic acid.
Retinoic acid (RA) has been reported to stimulate PA
production in murine teratocarcinoma stem cells (Strickland and
Mandavi, 1978), chick embryo fibroblasts (Wilson and Reich, 1978),
and a number of cultured human cell types derived from normal and
neoplastic tissues (Dano et al., 1985).
Retinoids, derivatives of vitamin A, have been shown to
influence cellular differentiation (Wolbach and Howe, 1925), induce
proteolytic activity in cultured explants of the chick embryo limb
bud (Fell et al., 1962), and promote the growth of experimental
tumors (Polliack and Levi, 1969).The potential relationship
between retinoid action and PA synthesis inspired some workers to
study the regulatory mechanism of this enzyme in several cell
types.50
Wilson and Reich (1978) demonstrated that RA enhancement of PA
production by chick embryo fibroblasts required protein and mRNA
synthesis.In the teratocarcinoma cell line F9, RA increased the
production of PA and a similar effect was observed in cAMP treated
cells.Retinoic acid and cAMP, taken together, had an apparent
synergistic effect on protease secretion; however, this effect was
not immediate but required several days to be manifested.This
delay may suggest that RA elevated cellular sensitivity to cAMP.
Other morphological changes beside PA production indicate that RA
induced the differentiation of embryonal carcinoma cells to
endoderm (Strickland and Mandavi, 1978).
6. Growth factors.
Basic fibroblast growth factor (bFGF) has been shown to
increase PA production in cultured bovine capillary endothelial
cells (Gross et al., 1982; Saksela et al., 1987), newborn rat
cultured astroglial cells (Rogister et al., 1988), human
endometrial adenocarcinoma cells (Presta et al., 1988), and
cultured breast tumor cells (Mira-y-Lopez et al., 1986).
Transforming growth factor (TGF -fl) inhibited PA activity in
capillary endothelial cells (Saksela et al., 1987), and stimulated
production of PAI-1 in human endometrial adenocarcinoma cells
(Presta et al., 1988) and human tumor cell line HT-1080 (Laiho et
al., 1987).
Fibroblast growth factor (FGF) induces cell proliferation and
protease production.Therefore, FGF may be involved in the
regulation of the growth of both normal and tumor cells.In
contrast, transforming growth factor -fl (TGF -fl) was shown to have51
both stimulatory and inhibitory properties on cellular growth in
vitro (Presta et al., 1988).Saksela and coworkers (1987)
evaluated the opposing effects of bFGF and TGF-fl on the regulation
of PA activity in bovine capillary endothelial cells (BCEC).They
found bFGF markedly increased PA production, while TGF-flcaused a
significant decrease in enzyme secretion.Administering bFGF and
TGF -fl simultaneously to BCEC resulted in the inhibition of the
bFGF-simulation of PA activity.The stimulatory effect of bFGF on
PA levels was due to the increased synthesis and secretion of PA.
The suppression of PA activity by TGF -fl may be a direct result of
the decrease in the rate of synthesis of PA or indirectly by
increasing synthesis of PAI-1 from endothelial cells.Prolonged
culture of BCEC in bFGF and TGF-fl diminished the TGF -fl inhibitory
effect; however, the bFGF stimulatory effect on PA activity was
maintained.The bFGF stimulation of PA production by BCEC is
important for the migration and proliferation of endothelial cells
as well as the degradation of the subcellular matrix during
angiogenesis.Transforming growth factor -fl also stimulated
synthesis and release of PAI-1 from human tumor cell line HT-1080,
which was rapidly deposited in the cellular substratum.Pulse-
phase experiments showed a relatively fast turnover of substratum-
associated PAI-1.Transforming growth factor -fl also inhibited the
anchorage-independent growth of HT-1080 cells at the same
concentrations necessary to induce PAI-1.These results indicate
that TGF -fl can modulate the extracellular proteolytic activity by
stimulating the secretion and deposition of PAI-1 into ECM (Laiho
et al., 1987).52
Epidermal growth factor (EGF) has been reported to enhance PA
activity in the HeLa cell line, cultured human foreskin
fibroblasts, and rat kidney cell line NRK-536-3-1 (Dano et al.,
1985).The stimulatory effect of EGF was observed on both
intracellular and extracellular PA activity in HeLa cells.The
induction of PA activity in these cells was blocked by actinomycin
D and cycloheximide, suggesting that EGF induces de novo synthesis
of PA in a manner dependent on the continued synthesis of PA mRNA
(Dano et al., 1985).
7.Other biochemical factors.
Dimethyl sulfoxide (DMSO) greatly stimulates the production of
cell-associated and secreted PA in auxotrophic mutants (cells that
can not metabolize carbohydrates) of the Chinese hamster ovary cell
line.Dimethyl sulfoxide stimulation of PA activity was completely
blocked by actinomycin D and cycloheximide, indicating that new
protein and mRNA synthesis were required for this process.
Moreover, the stimulatory effect of DMSO was lost when the cells
were hybridized with other complementary auxotrophic mutants,
suggesting that the effect may be related to the auxotrophic
mutation in this cell line (Carlsen, 1987).
Negatively charged phospholipids, contained within lipid
vesicles, have the ability to activate the latent form of PAI-1.
The presence of a net negative charge on the phospholipid head
group is essential for the activation process.In the presence of
negatively charged phosphatidylserine (PS), PAI-1 inhibited tPA 50-
fold more effectively than in the absence of these phospholipids.
Calcium ions interfered with the inhibitory activity of PS-53
activated PAI-1, indicating that Ca2+ ions may be involved in
regulating PAI-1 activity in the presence of negatively charged
phospholipids.In conclusion, negatively charged phospholipids may
play a critical role in controlling the fibrinolytic system by
local activation of PAI-1 (Lambers et al., 1987).
Tumor necrosis factor (TNF) enhanced the production of PAI by
cultured human endothelial cells from umbilical vein, 2-fold, and
from foreskin microvessels, 4- to 5-fold.This increase in PAI
production, accompanied by increased levels of PAI mRNA, indicated
that TNF induced PAI synthesis.In vivo experiments with rats
showed that TNF increased circulating PAI levels 5-fold.Tumor
necrosis factor did not change PAI levels in primary monolayer
cultures of rat and human hepatocytes.These results suggest that
vascular endothelial cells are the primary targets for TNF.
Furthermore, the induced PAI activity might decrease fibrinolysis
within the blood vessels (Van Hinsbergh et al., 1988).
Sodium butyrate (NaB) significantly reduced PA activities in
two human glioblastoma cell lines (SNB-19 and SNB-75).The lesser
PA activities in these cells correlated with greatly reduced
colonogenic properties, which is consistent with the suggested role
of PA in promoting tumor proliferation.The inhibition of PA
activity by NaB is most likely caused by a change in PA synthesis,
since a direct inhibition assay revealed no changes in PAI levels.
These results demonstrated that net cellular PA activity in glioma
cells is regulated by a balance between PA production and protease-
inhibitor levels.This balance can be altered by exogenous
modulators such as NaB (Gross et al., 1988).54
The stimulatory effect of dibutyryl cAMP (dbcAMP) on the
production of PA in a wide variety of cells is well documented.
However, data from one study suggested that the effect of dbcAMP on
PA induction in cultured human endothelial cells may be attributed
to the slow liberation of butyrate (Kooistra et al., 1987).They
based their suggestion on the observation that free butyrate, but
not 8-bromo-cAMP, resulted in the same increase in PA production as
dbcAMP.The enhancement of PA activity by butyrate was accompanied
by increased levels of PA mRNA.Butyrate, however, did not alter
PAI-1 synthesis significantly indicating that this compound
selectively induced PA production in endothelial cells.
Lipopolysaccharide (LPS), a mediator for the inflammatory
response, has been found to stimulate the production of PAI-1 from
human endothelial cells.This effect was accompanied by a
considerable increase in PAI-1 mRNA.Lipopolysaccharide-mediated
increases in PAI-1 mRNA is not dependent on protein synthesis,
since co-treatment of endothelial cells with cycloheximide caused a
superinduction of PAI-1 mRNA (Van Den Berg et al., 1988).
An extractable tPA cofactor from porcine coronary heart
endothelium has been reported to enhance the rate of plasminogen
activation by tPA.This novel cofactor increases Vmax for
plasminogen activation without affecting Km.The mechanism of
action of this cofactor differs from that of fibrin which
stimulates plasminogen activation by lowering the Km for
plasminogen.The activity of this endothelial cofactor is high in
coronary and aortic valve endothelium extracts, but not in fluids
or tissues lacking endothelium (Machovich et al., 1988).Other55
endogenous factor(s) have been shown to stimulate rat oocyte tPA
activity during meiotic maturation (Bicsak and Hsueh, 1989).
Dermatan sulphate (DS), a component of the extracellular
matrix, enhanced PA activity in the perfused rat hindquarters in a
dose-dependent fashion.Dermatan sulphate has been shown to have a
potent antithrombotic property.Therefore, it is reasonable to
suggest that DS facilitates clot lysis by stimulating PA release
from surrounding endothelial cells during vascular injury (Abbadini
et al., 1987).56
MATERIALS AND METHODS
Embryo Collection and Culture
Thirty-two crossbred beef cows from the Oregon State University
beef herd were estrous-synchronized with prostaglandin F2a (PGF2a;
Lutalyse, The Upjohn Co., Kalamazoo, MI) and superovulated with porcine
follicle stimulating hormone (pFSH; Schering Corp., Kenilworth, NJ).
Two 25-mg injections of PGF2a were administered i.m. 14 days apart (Day
0 = first PGF2a injection) to all cows.Porcine follicle stimulating
hormone injections were administered twice daily i.m. at dosages of 5,
4, 2, and 1 mg on Days 12, 13, 14 and 15, respectively.Estrous
detection was initiated 24 h after the second PGF2a injection.Cows
exhibiting estrus were either naturally mated at the onset of estrus and
at 12-h intervals thereafter, or artificially inseminated with one straw
of frozen semen at 0, 12, and 24 h after estrus onset.
Embryos were collected 8 days after mating either nonsurgically or
from slaughtered cows.In the non-surgical collection, uteri were
flushed with Dulbecco's phosphate buffered saline (PBS; Dulbecco and
Vogt, 1954) containing .5% bovine serum albumin (BSA; Sigma) and 10 m1/1
of an antibiotic-antimycotic solution (10,000 units penicillin, 10 mg
streptomycin and 25 Ag amphotericin B per ml in .9% sodium chloride;
Sigma).Excised uteri recovered at slaughter were flushed within 30
minutes with Ham's F-12 containing 10 m1/1 of the antibiotic-antimycotic
solution (Sigma).Uterine flushings were examined under a dissecting
microscope and embryos were recovered from the flushing by aspiration.
Recovered embryos were washed at least three times in microdrops of
Ham's F-12 with 1.5 mg/0 BSA and morphologically evaluated using an57
inverted stage-phase contrast microscope.Only morphologically normal
embryos were assigned to the various hormonal treatments.Embryos were
individually cultured in 35 Al microdrops under paraffin oil (Fisher
Scientific Co., Tustin, CA) in a humidified atmosphere of 5% CO2 in air
at 37°C for 5 days.At the initiation of culture and at subsequent 24 h
intervals, embryonic cell stage was recorded and overall embryonic
diameter (OD) was measured using an ocular micrometer.At 24 h
intervals, embryos were transferred to fresh microdrops and 15 Al of the
culture medium were recovered and frozen at -20°C until assayed for PA
activity.The remaining medium was also recovered and pooled for every
treatment and frozen at -20°C until zymography.Another 15 Al of medium
from a microdrop without embryos was recovered for every treatment to
correct for any spontaneous activation of plasminogen.At termination
of culture, embryos were recovered and frozen at -20°C until zymography.
Effect of Hormones and Inducers of Intracellular Messengers on PA
Production and OD by Cultured Bovine Embryos
Progesterone.Progesterone (Sigma) was initially dissolved in absolute
ethanol and further diluted to final concentrations of 10-6, 10-7,
and 10-8 g/ml with Ham's F-12 containing 15 mg/ml BSA.Two
controls were included in this experiment:Ham's F-12 with 15
mg/ml BSA and this medium with 1% absolute ethanol.Twelve
morphologically normal embryos were randomly assigned to each
treatment.
Dexamethasone.Four levels (0, 10-8, 10-7, and 10-6 M) of dexamethasone
(Sigma) were prepared by diluting a dexamethasone-ethanol stock
solution with Ham's F-12 with 1.5 mg/ml BSA.The same levels of58
absolute ethanol used to dissolve the drug was included in the
control treatment (0 level).Eleven to 13 embryos were randomly
assigned to each treatment.
Retinoic acid.Retinoic acid (Sigma) was dissolved in absolute ethanol
and diluted to 0, 10-8, 10-7, and 10-8 M with Ham's F-12
containing 1.5 mg /ml BSA.Twelve to 13 embryos were assigned
randomly to each treatment.
Estradiol -17fl.Estradiol -17fl (Sigma) was prepared with similar levels
as progesterone (0,10-8, 10-7, and 10-8 g/ml).Twelve to 14
embryos were randomly assigned to each treatment.
Phorbol myristate acetate and dibutyryl cyclic AMP.
Experiment 1.Phorbol-12-myristate 13-acetate (Sigma) was
dissolved in dimethyl sulphoxide (DMSO; Sigma) and diluted with
Ham's F-12 with 1.5 mg/ml BSA to a final concentration of 10
µg /ml.One percent of DMSO was added to Ham's F-12 with 1.5 mg/ml
BSA as the control treatment.Dibutyryl cAMP (dbcAMP; Sigma) was
diluted with Ham's F-12 containing 1.5 mg/ml BSA to 5 mM.A
control treatment of Ham's F-12 with 1.5 mg/ml BSA was included in
this experiment.Eight embryos were randomly assigned to each of
these four treatments.
Experiment 2.Phorbol 12-myristate 13-acetate was further diluted
with culture medium to 100 ng/ml, and dbcAMP was diluted to 0.5
mM.Two control treatments, one with 1% DMSO and the other with
only culture medium (Ham's F-12 with 1.5 mg/ml BSA), were included59
in this experiment.Seven to 10 embryos were randomly assigned to
each treatment.
Experiment 3.Phorbol 12-myristate 13-acetate was diluted to 1
ng/ml with Ham's F-12 containing 1.5 mg/ml BSA, and 1% DMSO was
added to the control treatment.Thirteen to 14 embryos were
randomly assigned to each treatment.
Assay for PA Activity
Plasminogen activator activities were determined by a modified
caseinolytic assay described by Menino and Williams (1987).The casein-
agar solution was prepared by combining 2% agarose (Sigma) with an equal
volume of warmed 2% nonfat milk (Carnation Co., Los Angeles, CA),
dissolved in 0.038 M tris (hydroxymethyl)-aminomethane-0.1 M glycine
buffer containing 0.195 g/1 CaC122 H2O and 0.325 g/1 sodium azide.
Fifteen milliliters of the warmed mixture was pipetted into 85 x 65 x 2
mm plastic diffusion plates and allowed to solidify at room temperature.
Plasminogen activator activities were determined by combining 15 Al of
150 Ag/ml human plasminogen (Sigma) with 15 Al of either conditioned
medium or 0,.0009, .0045, .0091, .0455, and .0909 mU /ml urokinase (E.C.
3.4.21.7; Sigma) as the standard and incubated for 15 min at 37°C.
Twenty-five microliters of the incubated mixture were aliquoted into 4
mm diameter wells cut in the casein-agar gel plate and incubated at room
temperature for 24 h.Plates were fixed for 15 min with 3% acetic acid
and rinsed in tap water; the resultant caseinolytic zones were measured
with an electronic digital calipar.Concentrations of PA in the
conditioned medium were determined from equation of the line
calculations for caseinolytic ring diameter by log urokinase60
concentration.The amount of the embryonic PA was determined by
deducting the amount of PA in the medium without an embryo from the
amount in the medium with an embryo for each 24-h interval.Plasminogen
activator activity was expressed as milliunits PA x 104m1-1 h-1
Sodium Dodecvl Sulfate-Polvacrvlamide Gel Electrophoresis (SDS-PAGE) and
Zvmoqraphv
Molecular weights (MW) of PA were determined with the Protean Dual
Slab Cell electrophoresis apparatus (Bio-Rad Laboratories, Richmond, CA)
under non-reducing conditions using a modification of the SDS-PAGE and
zymography techniques described by Granelli-Piperno and Reich (1978) and
Vassalli and coworkers (1984).Media samples representing each 24-h
interval were combined with equivalent volumes of sample buffer (5% SDS,
20% glycerol, 0.0025% bromophenol blue in 0.125 M Tris-HC1 buffer).
Embryos were thawed and homogenized by repeated aspiration with a
micropipette before adding sample buffer.Urokinase standards at 1,.5
and .1 mU/m1 were used as references and to indicate the sensitivity of
the assay.A MW standard (Bio-Rad) with the following proteins:
phosphorylase b (97.4 kD), bovine serum albumin (66.2 kD), ovalbumin
(42.7 kD), carbonic anhydrase (31 kD), soybean trypsin inhibitor (21.5
kD), and Lysozyme (14.4 kD) was included in each 160 x 135 x 1.5 mm
electrophoretic slab gel.Urokinase and MW standards were diluted with
sample buffer.One hundred microliters of samples and standards were
pipetted into castellated wells in a 4% acrylamide stacking gel with a
12% separating gel.Electrophoresis was started at 15 mA through the
stacking gel and 30 mA through the separating gel until the dye front
reached the bottom edge of the separating gel.Following61
electrophoresis, the lane containing the MW standards was cut and
stained with .05% Commassie Brilliant Blue (Bio-Rad) in 65/25/10
water/isopropanol/acetic acid for 4-8 h and destained in 80/10/10
water/isopropanol/acetic acid overnight.The gel with the remaining
lanes was gently agitated in 2.5% Triton X-100 (Sigma) for 30 min to
remove the SDS, rinsed with distilled water 3 times, and incubated in
PBS for 30 min.The gel was placed on plastic wrap and a casein-agar
gel containing human plasminogen was carefully applied to the surface of
the polyacrylamide gel.The casein-agar plates preparation was similar
to those used in the caseinolytic assay with two exceptions; purified
human plasminogen was added to the warmed mixture of 2% casein and 2%
agarose to yield a final concentration of 25-30 gg/m1 and 15 ml of this
mixture was carted onto a warmed 13 x 10 cm glass plate.The gel
sandwich (acrylamide gel + casein-agar gel) was incubated at room
temperature for 40-48 h and observed for localized lysis periodically.
Incubation was terminated by fixing the casein-agar gel with 3% acetic
acid for ten min.Protease mobility was determined during incubation
period and after fixing the gel by measuring the distance from the edge
of the separating gel to the center of the lytic bands in each lane.
Molecular weights of PA in the conditioned media, embryo homogenates and
urokinase standards were determined from equation of the line
calculations for relative mobility by log MW derived from the MW
standards.Casein-agar gels were stained with 0.1% Amido Black (Bio-
Rad) in 20/10/70 water/acetic acid/methanol for 3-4 min and destained in
70/10/20 methanol/acetic acid/water overnight.62
Statistical Analyses
With the exception of the PMA treatments (10 Ag/m1 and 100 ng/ml),
statistical analyses were performed on data obtained from embryos that
successfully completed hatching.Statistical comparisons were made by
two-way analyses of variance where hormonal treatment and time in
culture were the main effects.Duncan's new multiple range test was
used for multiple comparisons when appropriate.Molecular weights of PA
were determined using correlation-regression analysis (Steel and Torrie,
1980).63
RESULTS
Embryo Recovery
A total of 444 ova were collected from thirty-two cows with an
average of 14 ova per cow.Thirty-five percent of these ova were
comprised of unfertilized ova and degenerate or poor embryos.The
remaining 65% were morphologically good embryos (287 embryos).The
percentage of embryos that successfully completed in vitro hatching was
93.2% for all experiments.
Effects of Hormones and Inducers of Intracellular Messengers on PA
Production and OD by Cultured Bovine Embryos
Progesterone.Fifty-nine morphologically normal embryos were assigned
to the various treatments in this experiment and 54 (92%) embryos
hatched.Ethanol vehicle (Figures 1 and 2), at levels used to
dissolve progesterone, had no effect (P>.1) on PA production or OD
when compared to the control of Ham's F-12 with 15 mg/ml BSA.
Progesterone at levels of 10-6, 10-7, and 10-8 g/ml (Figures 1 and
2) neither affected PA production nor OD (P>.1); however, culture
interval affected (P<.05) both PA production and OD.No
interaction between time and hormonal level was observed (P>.1).
Figure 1 shows the relationship between time and PA production.
At the beginning of the culture (24 h to 48 h) PA production
remained low with no change (P>.05).Plasminogen activator
production, however, increased (P<.05) at 72 h of culture, peaked
at 96 h, and plateaued thereafter.On the other hand, culture
time increased (P<.05) OD where maximal OD was attained at 72 h
then declined (P<.05) at the end of the culture period (Figure 2).64
Dexamethasone.Forty-six morphologically good embryos were randomly
assigned to four treatments (0,10-8, 10-7, 10-8 M) of
dexamethasone.Forty-four embryos (96%) successfully completed
hatching in culture.Plasminogen activator production and changes
in OD for embryos hatched cultured in dexamethasone at levels
indicated above are depicted in Figures 3 and 4.Plasminogen
activator production and embryo OD were not affected (P>.1) by
dexamethasone treatments.Time of culture, on the other hand,
affected PA production and OD (P<.05) and no interaction was
detected (P>.05) between the main effects.A progressive increase
was observed in PA production (Figure 3) starting at 24 h which
reached a maximum at 96 h, then decreased at 120 h of culture
(P<.05).Similarly, OD increased (P<.05) during the first 48 h,
peaked at 72 h then diminished at 96 and 120 h of culture
(Figure 4).
Retinoic acid.Forty-four embryos were equally distributed over four RA
levels (0, 10-8, 10-7, 10-8 M).Forty-one embryos (93%)
successfully escaped from their zona pellucida.Retinoic acid did
not affect (P>.1) PA production or OD (Figures 5 and 6).Time of
culture had a great effect (P<.01) on PA production and OD and no
interaction was observed between the RA treatments and time of
culture (P>.1).Plasminogen activator production (Figure 5)
remained low at the 24 and 48 h intervals (P>.05), increased at 72
h and persisted throughout the culture period (P<.05).Embryo OD
(Figure 6) increased in a progressive fashion (P<.05) and at 72 h
reached a maximal size which remained constant through 96 h then
declined toward the end of culture (P<.05).65
Estradiol-17fl.Forty-eight normal embryos were equally distributed
throughout 4 levels of estradiol 17$ (0, 10-8, 10-7, 10-8 g/ml).
Forty-five (94%) embryos hatched in vitro.No effect was observed
in PA production and OD (P>.1) between the control treatment and
treatments containing E2 (Figures 7 and 8).In contrast, culture
time greatly affected both PA production and OD (P<.01).
Interaction between the treatment factor and time of culture was
not observed (P>.1).Plasminogen activator production (Figure 7)
remained unchanged at the first 48 h (P>.05), increased at 72 h
(P<.05) and plateaued thereafter.Moreover, OD (Figure 8)
increased during the first 48 h (P<.05) and reached the largest
size at 72 h, remained constant to 96 h then declined at 120 h
(P<.05).
Phorbol myristate acetate and dibutyryl cyclic AMP.
Experiment 1.Thirty-two embryos were randomly assigned to four
treatments (10 Ag/m1 PMA, 5 mM dbcAMP, 1% DMSO, and Ham's F-12
with 1.5 mg/ml BSA as the control).Percentage of embryos
hatching in PMA, dbcAMP, DMSO, and control were 0, 63, 88, and
100, respectively.Phorbol myristate acetate at 10 Ag/m1 caused
embryos to degenerate within the first 24 h.Dibutyryl cAMP also
reduced the number of embryos hatching in vitro and caused embryo
degeneration toward the end of culture.Plasminogen activator
production was not affected (P>.1) by dbcAMP when compared to the
control treatment (Figure 9A).Production of this enzyme
increased (P<.01) from 24 h to 48 h, plateaued during 72 and 96 h
(P>.05) then decreased (P<.05) at the end of culture.No66
interaction was observed between the two main effects (P>.1).A
time-dependent decrease in OD (P<.01) was observed due to 5 mM
dbcAMP; OD started to decrease after 48 h and remained low
throughout the culture period (Figure 9B).The interaction
between time of culture and treatment was apparent (P<.05).
Dimethyl sulphoxide decreased PA production (P<.01) particularly
during the first 72 h of culture.Levels of PA started to
increase after 72 h reaching a comparable level as the control
treatment (Figure 10A).Embryo OD was not affected (P>.1) by DMSO
and remained unchanged during the first 48 h, increased to the
largest size at 72 h (P<.05) and maintained the same size
throughout the rest of culture (Figure 10B).Embryos cultured in
10 µg /ml PMA did not hatch and degenerated during the first 24 h
of culture.Compared to embryos cultured in DMSO, PMA treatment
and time of culture did not affect (P>.1) PA production (Figure
11A).Embryo OD was lower (P<.01) in PMA than DMSO and remained
constant throughout the culture period (Figure 11B).
The second trial was designed to eliminate the side effect
of the high levels of PMA and dbcAMP observed in the first trial.
Thirty-three morphologically normal embryos were assigned to the
following treatments:100 ng/ml PMA, .5 mM dbcAMP, 1% DMSO, and
control treatment (Ham's F-12 with 1.5 mg/ml BSA); hatching rates
were 17, 90, 71, and 80 percent, respectively.There was no
effect (P>.1) on PA production due to .5 mM dbcAMP (Figure 12A),
but time of culture exerted a significant affect on the production
of this enzyme (Figure 12A).Plasminogen activator increased
(P<.05) at 48 h interval and remained unchanged during 72 and 96 h67
intervals then declined toward 120 h.In contrast, OD was
decreased (P<.05) in embryos cultured in .5 mM dbcAMP, however,
time of culture and the interaction were not significant (Figure
12B).The results obtained for the DMSO effect on PA production
were similar to those presented in experiment 1 with the exception
of the effect on OD (Figure 13); an increase (P<.01) in OD was
detected in embryos cultured in medium containing DMSO (Figure
13B).On the other hand, no significant effect on OD was observed
with culture time.Phorbol myristate acetate at level of a 100
ng/ml had a similar effect on PA production and OD as in
experiment 1(Figure 14A and B), however, time of culture during
this experiment significantly influenced PA production, which was
low during the first 72 h increased (P<.05) at 96 h and 120 h
(Figure 14A).
Experiment 3.Phorbol myristate acetate was diluted to a final
concentration of 1 ng/ml.Twenty-six embryos were equally divided
into two treatments, one containing 1 ng/ml PMA and the other
containing 1% DMSO.Twenty-four embryos (92%) hatched in vitro.
The toxic effect of PMA on embryos observed during the previous
experiments was eliminated in this experiment.Phorbol myristate
acetate compared to DMSO treatment did not (P>.1) affect PA
activity (Figure 15A), yet OD were greater (P<.05) in the presence
of PMA (Figure 15B).Time of culture did not affect PA production
(P>.05) during the first 72 h, at 96 h production increased
(P>.05) greatly and remained at the same level at 120 h (Figure
15A).Also, time of culture exerted a significant effect on OD
which increased (P<.05) at 48 h, leveled at 72 and 96 h, then68
decreased (P<.05) toward the end of culture (Figure 15B).No
interactions between treatment and culture time were observed with
regard to PA production and embryo OD.
SDS-PAGE and Zymography.Because of concentration differences due to
interval of medium recovery, media from hormonal treatments were
combined and compared to media obtained from control treatments.
Molecular weights of urokinase standards, PA in embryo homogenates
and culture media are displayed in Table 1.Urokinase standards
showed two bands at 36.8 ± 0.8 and 52.4 ± 1.2 kD for the low and
high MW forms, respectively.The MW of PA in embryo homogenates
and media at 24, 48, 72, 96 and 120-h intervals were 47.2 ± 0.6,
47.1 ± 0.9, 47.1 ± 0.9, 46.3 ± 1.5, 46.7 + 0.9, and 47.0 + 0.6 kD,
respectively.The pattern of the MW of PA observed in both the
embryo homogenate and the culture media indicates that bovine
embryos secrete a urokinase-type plasminogen activator (Figure
16).69
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Figure 1. Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 15 pg/m1 BSA containing 0
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Figure 9A. Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 1.5 mg/ml BSA containing 0
( ), or 5( - -) mM dibutyryl cAMP (dbcAMP).Error
mean square is 0.008.
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Figure 9B. Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 0( ), or 5 (-
-) mM dibutyryl cAMP (dbcAMP).Error mean square is
2583.78
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Figure 10A.Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 1.5 mg/ml BSA containing 0
( ), or 1 (----) percent dimethyl sulfoxide (DMSO).
Error mean square is 0.004.
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Figure 10B.Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 0( ), or 1
(- -) percent dimethyl sulfoxide (DMSO).Error mean
square is 3180.79
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Figure 11A.Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 1.5 mg/ml BSA containing 1
(---) percent dimethyl sulfoxide (DMSO) or 10 (- -)
µg /ml phorbol-12-myristate 13-acetate (PMA).Error mean
cnuara ic n nric
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Figure 11B. Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 1(---) percent
dimethyl sulfoxide (DMSO), or 10 Ag/m1 phorbol
12-myristate 13-acetate (PMA).Error mean square is 1430.80
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Figure 12A. Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 1.5 mg/ml BSA containing 0
(---) or 0.5 mM dibutyryl cAMP (dbcAMP).Error
mean square is 0.027.
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Figure 12B.Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 0 (---)or 0.5
(- -) dibutyryl cAMP (dbcAMP).Error mean square is
5802.81
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Figure 13A.Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 1.5 mg/ml BSA containing 0
(---) or 1 percent dimethyl sulfoxide (DMSO).
Error mean square is 0.032.
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Figure 13B. Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 0 (---) or 1
percent dimethyl sulfoxide (DMSO).Error mean
square is 5889.82
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Figure 14A.Plasminogen activator production by bovine embryos
cultured in Ham's F-12 with 1.5 mg/ml BSA containing 1
(---) percent dimethyl sulfoxide (DMSO) or 100
ng/ml phorbol 12-myristate 13-acetate (PMA).Error mean
square is 0.007.
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Figure 14B.Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 1(---) percent
dimethyl sulfoxide (DMSO) or 100 ng/ml phorbol
12-myristate 13-acetate (PMA).Error mean square is 2949.83
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Figure 15A.Plasminogen activator production by bovine embryos
cultured in Ham's F -12 with 1.5 mg/ml BSA containing 1
(---) percent dimethyl sulfoxide (DMSO) or 1
ng/ml phorbol 12-myristate 13-acetate (PMA).Error mean
square is 0.013.
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Figure 15B. Embryonic overall diameter of bovine embryos cultured in
Ham's F-12 with 1.5 mg/ml BSA containing 1(---) percent
dimethyl sulfoxide (DMSO) or 1 ng/ml phorbol 12-
myristate 13-acetate (PMA).Error mean square is 5945.84
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Figure 16. A representative zymograph of urokinase standards and
embryonic plasminogen activators.Lane 1, urokinase
standards; Lane 2, embryo homogenate; Lane 3, conditioned
medium; Lane 4, stained polyacrylamide gel of molecular
weight standards.Arrow heads A and C, high MW and low MW
form of urokinase; arrow head B, embryonic plasminogen
activator.85
Table 1.Molecular weights (KD) of urokinase standards and
plasminogen activators produced by bovine embryos.
Source n X + SEa
Urokinase
Low MW form 19 36.3 + 0.8
High MW form 19 52.4 + 1.2
Embryo homogenates 6 47.2 + 0.6
Medium
24 h 2 47.1 + 0.9
48 h 2 47.1 + 0.9
72 h 3 46.3 + 1.5
96 h 3 46.7 + 0.9
120 h 3 47.0 + 0.6
a Mean ± standard error of the mean.86
DISCUSSION
Endocrine regulation of plasminogen activator (PA) has been
studied in various reproductive processes.The increase in PA activity
during the ovulatory process is highly correlated to the preovulatory
surge of gonadotropins (Beers et al., 1975; Beers et al., 1975;
Strickland and Beers, 1976; Reich et al., 1985; Canipari and Strickland,
1986; Harlow et al., 1987; Liu et al., 1987; Bicsak et al., 1989).
Follicle stimulating hormone stimulates PA production from Sertoli cells
and segments of seminiferous tubule during spermatogenesis (Lacroix et
al., 1981; Marzowski et al., 1985; Nettle et al., 1986; Coombs et al.,
1987).These studies clearly establish the close relationship between
PA activity and the hormonal profile during ovulation and
spermatogenesis.Moreover, much evidence has been presented indicating
an important physiological role for PA in these processes.Therefore,
examining the effect of hormones on embryonic PA may provide some
insight on the significance of this protease during early bovine
embryogenesis.
In this study, several known modulators of PA have been evaluated
in cultured Day 8 bovine embryos.Progesterone, estradio1-17#,
dexamethasone, and retinoic acid did not affect the production of PA by
cultured bovine embryos.Furthermore, these modulators neither affected
embryo overall diameter nor hatching rate.Estradiol -17$ increases PA
activity in human breast carcinoma cell lines MCF-7 (Dickerman et al.,
1989) and stimulates uptake of plasminogen by the mouse uterus (Finlay
et al., 1983).Retinoic acid stimulates PA production in chick embryo
fibroblasts and muscle cells (Wilson and Reich, 1978; Miskin et al.,87
1978).Estradio1-17fl and retinoic acid stimulation of PA production in
these systems may be due to direct activation of mRNA synthesis.On the
other hand, progesterone and dexamethasone have been shown to stimulate
the production of an inhibitor that decreases plasminogen activation in
several tissues including porcine endometrium (Fazleabas et al., 1982),
rat granulosa cells (Harlow et al., 1987) and bovine Sertoli cells
(Coombs and Jenkins, 1988).However, dexamethasone has been shown to
have no effect on PA production by human melanoma cells (Roblin and
Young, 1980) and rat ovarian granulosa cells (Strickland and Beers,
1976).Ovarian steroids also did not stimulate PA production in rat
granulosa cells (Strickland and Beers, 1976; Reich et al., 1985).
The effect of ovarian steroids on early embryo development has
been studied extensively in rodents and pigs.These hormones could act
directly on the embryo, which would be a target tissue, or indirectly
through the genital tract, which would provide the proper
microenvironment required for embryos during the preimplantation period.
Transport of mouse embryos through the oviduct, cleavage rate and
transformation of morulae to blastocysts were delayed in females
ovariectomized on Day 2 of pregnancy.Estradiol -17$ and progesterone
injected for 3 days after ovariectomy restored embryo transport rate,
cleavage rate, and transformation rate to normal levels (Roblero and
Garavagno, 1979).Estrogen also induced uptake of nucleic acid
precursors in cultured mouse blastocysts (Harrer and Lee, 1973) and is
required for implantation in rodents (Smith, 1968; Smith and Biggers,
1968).In pigs, estradiol-17$ is important for the transformation of
the compacted morulae to the cavitated blastocysts (Niemann and
Elsaesser, 1986).Furthermore, embryonic synthesis of estrogens88
increases dramatically at Day 12 of pregnancy which appears to be
important in maternal recognition of pregnancy (Heap et al., 1979).
Ovarian steroids, dexamethasone, and retinoic acid in the present study
did not affect the viability of the bovine embryo in vitro.There are
three possible explanations for the lack of effects of these hormones on
preimplantation bovine embryos.The first possibility is that ovarian
steroids may affect embryos indirectly through the stimulation of
genital tract motility and secretions.Wilmut and coworkers (1985)
found that asynchrony between embryo donor and recipient increases
embryo loss, indicating the importance of the close relationship between
the maternal hormone profile and embryo stage.The second possibility
is concerned with the capability of the embryo to synthesize its own
hormones, which can act in paracrine fashion to regulate early events of
embryo development.Measurable concentrations of estrogen, progesterone
and steroidogenic enzymes have been detected in the embryos of the mouse
(Sengupta et al., 1982; Wu, 1987), rabbit (Dickmann et al., 1975;
Borland et al., 1977), pig (Perry et al., 1973; Niemann and Elsaesser,
1987), horse (Paulo and Tischner, 1985) and cow (Shemesh et al., 1979).
Finally, the ability of the embryo to achieve normal development to the
blastocyst stage in vitro or in the oviduct of other species regardless
of their hormonal status, signifies a considerable autonomy in early
embryonic development (Brinster, 1963; Betteridge and Flechon, 1988).
The normal growth of cultured bovine embryos observed in this study
supports the existence of an endogenous control mechanism which
contributes to the independence of the embryo from maternal hormones
during in vitro development.89
Although PA production by cultured bovine embryos was not effected
by the hormonal treatments, a substantial increase in this enzyme was
observed at particular intervals during culture.The temporal pattern
of PA production was consistent in all experiments.Plasminogen
activator production was relatively low during the first 48 h of
culture, increased at 72 h, peaked at 96 h, then plateaued thereafter.
Some slight deviations from this pattern were noted with dexamethasone,
where PA production decreased toward the end of culture, and estradiol-
17#, where peak PA production was attained at 72 h then plateaued
thereafter.Moreover, PA production by embryos cultured in the presence
and absence of estradiol -17fl was lower than the levels observed in the
other experiments.Kaaekuahiwi and Menino (1989) observed that cow
source significantly affected embryo overall diameter and PA production
by bovine embryos developing in vitro.Different cows were used as
embryo donors for every experiment, therefore it is conceivable that
variations in PA production between experiments may be due to
differences in embryo donors.
The majority of embryos completed hatching before 72 h.Peak
production of PA coincided to the period where the greatest embryonic
diameter was attained, which occurred at 24 to 48 h after hatching.
This is consistent with the finding of Kaaekuahiwi and Menino (1989),
but different from the earlier observation of Menino and Williams
(1987).The latter observed that peak PA production was associated with
embryos initiating the hatching process; however, those investigators
used day 5 to day 6 embryos and cultured them for 12 days.In spite of
these differences the patterns of PA production by bovine embryos
developing in vitro were similar.Other investigators working with90
different species found similar results.A biphasic pattern of PA
production has been reported for the mouse, where the first phase
corresponds to trophoblast invasiveness and the second to acquisition of
the migratory capability by differentiated embryonic cells (Sherman et
al., 1976; Strickland et al., 1976).Porcine embryos developing in
vitro secrete PA in a biphasic pattern, where the initial phase
coincides with blastocyst elongation, and the second corresponds to the
period of increased embryonic DNA content (Fazleabas et al., 1983).
Dibutyryl cAMP, a known inducer of cAMP-dependent protein kinase
A, has been found to stimulate the production of PA in various types of
cells (Beers et al., 1975; Hettle et al., 1986; Queenan et al., 1987) by
promoting the transcriptional activity of the PA gene (Nagamine et al.,
1983; Roesler et al., 1988).In this study, although dbcAMP did not
affect PA production, a progressive decrease in OD was observed.This
inhibitory effect persisted, but to a lesser extent, when the dbcAMP
concentration was reduced tenfold.This is not surprising, since cAMP
has been hypothesized to diminish during preimplantation stages of
development (Robison, 1972).Moreover, Fisher and Gunaga (1975) have
reported that mouse blastocyst development was retarded when cAMP
accumulation was induced by theophylline, an inhibitor of intracellular
breakdown of cAMP.High levels of cAMP are generally associated with
inhibition of cellular proliferation (Bombik and Burger, 1973),
presumably through inhibition of the rate of replication (Thomas et al.,
1973).In contrast, Manejawala and coworkers (1986, 1989) demonstrated
that cAMP analogs, which activate the cAMP-dependent protein kinase,
stimulate the rate of blastocoel expansion and Na+ uptake by mouse
preimplantation embryos, suggesting a possible function for cAMP in91
blastocoel formation.The apparent paradox between the observations of
Manejawala et al. (1986, 1989) and our results could be explained by
differences in the duration of culture.While embryos in this study
were cultured for 5 days, Manejawala and his colleagues incubated
embryos for only 8 h.Furthermore, our results with bovine embryos
demonstrated that dbcAMP was without any effect on OD during the first
24 h.The inhibitory effect of dbcAMP was exerted at later intervals of
culture, suggesting that prolonged exposure to this compound is
required.
Phorbol 12-myristate 13-acetate (PMA), a potent tumor promotor,
has been found to enhance PA activity in many cell types (Wigler et al.,
1970; Vassalli et al., 1977; Quigley, 1979) through the activation of
phospholipid-dependent protein kinase C (Castagna et al., 1982).
Therefore, the possibility that the embryo utilizes protein kinase C in
regulating PA production was investigated.Although PMA inhibited PA
production by bovine embryos during the first 72 h of culture, this
inhibitory effect was attributed to DMSO which was used to dissolve the
PMA in the culture medium.Results from the first and second trials
comparing the effect of DMSO to the control treatment suggests that this
polar solvent inhibited PA production, particularly during the first 72
h of culture.Phorbol myristate acetate neither potentiated nor
decreased PA production when compared to DMSO.Accordingly, the
inhibitory effect of PMA on PA activity was largely due to DMSO.
Carlsen (1987), however, found that DMSO concentrations up to 2.5%
greatly stimulated the production of PA in Chinese hamster ovary cells,
and new protein and RNA synthesis were required for this process.The
inhibitory effect of DMSO on PA production observed in this study was92
not accompanied by any changes in embryo viability; in contrast, a
stimulatory effect was observed on OD during the second trial.The
reason for this inhibitory effect of DMSO is not clear, hence, further
investigation is required to elucidate the mechanism by which DMSO
inhibited PA production.
Embryos cultured in the presence of high levels of PMA failed to
hatch, showed signs of degeneration within 24 h, and completely
degenerated by 72 h of culture, whereas PMA at low concentrations
significantly stimulated embryonic diameter.Phorbol esters have been
shown to stimulate RNA synthesis (Sivak and Van Duuren, 1970), increase
cell division (Driedger and Blumberg, 1977), enhance protein synthesis
(Hiwasa et al., 1982), and increase the specific activity of cell
membrane associated Na+/e-ATPase (Sivak et al., 1972).Thus, the
effect of PMA on bovine embryo development reported herein may be due to
stimulation of cell division and/or an increase in blastocoel expansion
due to enhancement in Na+/e-ATPase activity.Ultimately, these
processes would lead to an increase in embryonic diameter.It is
interesting that PMA, which promotes tumor growth, exerted such an
effect on the embryo, supporting the relevance of embryos in cancer
research as suggested by Betteridge and Flechon (1988).Embryos
cultured in the presence of high levels of PMA degenerated, yet
liberated measurable amounts of PA.Degeneration of the embryo is
accompanied by progressive cell lysis, releasing cell-associated PA into
the medium which explains the persistence of enzyme activity in
degenerating embryos.
Zymographic analysis indicated that bovine embryos produce uPA.
Analysis of embryonic tissues and media collected during the culture93
period revealed great similarities in MW between the released- and cell-
associated forms of PA.The MW of bovine embryonic PA is similar to
mouse uPA reported by Marotti and coworkers (1982); however, in addition
to uPA, mouse embryos produce tPA which was not detected in the present
study.It is possible that tPA is produced during advanced stages of
embryogenesis.
The exact physiologic role of PA in early embryogenesis is not
clear.However, the ability of embryos of different species to produce
this enzyme during early stages of development prompted several workers
to implicate PA in various processes such as embryo hatching (Menino and
Williams, 1987), tissue remodeling and proliferation (Fazleabas et al.,
1983), migration of parietal endoderm (Strickland et al., 1976) and
implantation (Strickland et al., 1976; Sherman, 1980; Axelrod, 1985).
The fact that DMSO in this study inhibited PA production during the
first 72 h of culture without affecting embryo hatching rate suggests
that this protease is not involved directly in the hatching process.
Menino and Williams (1987) concluded that plasminogen activation
accelerated the hatching process without increasing the rate of
hatching, and they suggested the involvement of other factors beside PA
in this process (Menino et al., 1989).Furthermore, Sherman (1980) has
suggested that PA is not directly involved in hatching.In the present
study, maximum concentrations of PA occurred at about 48 h after
hatching which coincided with blastocyst expansion and cellular
proliferation and migration.Endodermal cells of the bovine embryo
begin to migrate at Day 8 and their migration involves the interaction
with an extracellular matrix (Betteridge and Flechon, 1988).
Plasminogen activator, particularly uPA, has been implicated in the94
migration of cultured cells (Ossowski et al., 1975) as well as parietal
endoderm in mouse embryos (Strickland et al., 1976).Accordingly, PA
released by bovine embryos may play a role in facilitating cellular
migration during the preimplantation period.
In conclusion, bovine preimplantation embryos developing in vitro
release an appreciable amount of uPA, which is neither dependent upon
nor influenced by hormonal regulation.With the exception of PMA and
dbcAMP, the hormones tested herein showed no effect on embryonic
diameter.Although this study did not provide a conclusive role for PA
in early embryo development, this enzyme may be important for cellular
movement during bovine embryogenesis.Further research is required to
elucidate the function of PA during the early stages of bovine embryo
development.95
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